<PAGE>
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
____________
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): February 1, 1996
INTERNATIONAL REMOTE IMAGING SYSTEMS, INC.
(EXACT NAME OF REGISTRANT AS SPECIFIED IN CHARTER)
Delaware 0-9767 94-2579751
(STATE OR OTHER JURISDICTION (COMMISSION (IRS EMPLOYER
OF INCORPORATION) FILE NUMBER) IDENTIFICATION NO.)
9162 Eton Avenue, Chatsworth, California 91311
(ADDRESS OF PRINCIPAL EXECUTIVE OFFICES) (ZIP CODE)
Registrant's telephone number, including area code: (818) 709-1244
<PAGE>
ITEM 2. ACQUISITION OR DISPOSITION OF ASSETS.
On February 1, 1996, the Registrant ("IRIS") and Norfolk Scientific, Inc.,
d/b/a StatSpin Technologies, ("StatSpin") effected a combination of their
respective businesses through a merger of StatSpin Acquisition Corporation, a
newly-formed Massachusetts corporation and wholly-owned subsidiary of IRIS
("Merger Sub"), with and into StatSpin, with StatSpin being the surviving
corporation and becoming a wholly-owned subsidiary of IRIS (the "Merger").
StatSpin, based in Norwood, MA, manufactures special purpose centrifuges and
other small instruments widely used in clinical, veterinary, physician's office
and research laboratories and distributes its products primarily through the
Curtin Matheson Scientific Division of Fisher Scientific and a number of leading
distributors to the physician's office and veterinary laboratories markets.
StatSpin had net sales of $2.9 million in its last fiscal year.
IRIS completed the acquisition of StatSpin for approximately 340,000 shares
of IRIS common stock and the assumption of options and warrants to purchase an
additional 126,000 shares of IRIS common stock. The total consideration paid by
IRIS is valued at $3,000,000 based on a value of $7.58 per share of IRIS common
stock which was the average closing price for the ten-day period ending on
January 26, 1996. The acquisition is expected to qualify as a pooling-of-
interests for financial accounting purposes.
IRIS plans to continue current StatSpin operations as well as its channels of
distribution with StatSpin operating as an IRIS subsidiary. Dr. Thomas F.
Kelley, StatSpin founder and chief executive, will be the General Manager of the
new subsidiary and also will become a member of the IRIS Board of Directors.
ITEM 7. FINANCIAL STATEMENTS AND EXHIBITS.
(A) FINANCIAL STATEMENTS OF BUSINESS ACQUIRED.
See Exhibit 99.1.
(B) PRO FORMA FINANCIAL INFORMATION.
See Exhibit 99.2.
(C) EXHIBITS.
1 -- Agreement and Plan of Merger by and among IRIS, StatSpin, and
Merger Sub dated as of January 31, 1996;
23.1 -- Consent of KPMG Peat Marwick LLP;
99.1 -- StatSpin Financial Statements;
99.2 -- Unaudited Pro Forma Condensed Financial Statements.
-2-
<PAGE>
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
INTERNATIONAL REMOTE IMAGING SYSTEMS,
INC.
Date: February 16, 1996 By: /s/ E. Eduardo Benmaor
-----------------------------------------
E. Eduardo Benmaor
Controller, Principal Accounting Officer
and Secretary
-3-
<PAGE>
EXHIBIT INDEX
1 -- Agreement and Plan of Merger by and among IRIS, StatSpin,
and Merger Sub dated as of January 31, 1996;
23.1 -- Consent of KPMG Peat Marwick LLP;
99.1 -- StatSpin Financial Statements;
99.2 -- Unaudited Pro Forma Condensed Financial Statements.
-4-
<PAGE>
================================================================================
AGREEMENT AND PLAN OF MERGER
by and among
INTERNATIONAL REMOTE IMAGING SYSTEMS, INC.,
a Delaware corporation,
NORFOLK SCIENTIFIC, INC.,
a Massachusetts corporation
doing business as StatSpin Technologies
and
STATSPIN ACQUISITION CORPORATION,
a Massachusetts corporation
Dated as of January 31, 1996
================================================================================
<PAGE>
AGREEMENT AND PLAN OF MERGER
This AGREEMENT AND PLAN OF MERGER (the "AGREEMENT") is made and entered
into as of January 31, 1996, by and among INTERNATIONAL REMOTE IMAGING SYSTEMS,
INC., a Delaware corporation ("IRIS"), NORFOLK SCIENTIFIC, INC., a Massachusetts
corporation doing business as "StatSpin Technologies" ("STATSPIN"), STATSPIN
ACQUISITION CORPORATION, a Massachusetts corporation and wholly-owned subsidiary
of IRIS ("MERGER SUB"), with reference to the following facts:
A. IRIS and StatSpin desire to effect a combination of their respective
businesses through a merger of StatSpin and Merger Sub.
B. The Boards of Directors of IRIS and StatSpin believe it is in the best
interests of each company and their respective stockholders to consummate such
combination on the terms and conditions set forth herein.
C. The parties intend that such acquisition qualify as a tax-free
"reorganization" within the meaning of Section 368(a) of the Internal Revenue
Code of 1986, as amended, and a "pooling of interests" under Opinion No. 16 of
the Accounting Principles Board.
NOW, THEREFORE, based on the above premises and in consideration of the
mutual covenants and agreements contained herein, the parties agree as follows
(capitalized terms not otherwise defined herein have the meanings set forth in
Section 9):
SECTION 1
THE MERGER AND RELATED MATTERS
1.1 THE MERGER. At the Effective Time, and subject to and upon the terms
and conditions of this Agreement and the applicable provisions of the
Massachusetts Business Corporation Law, (a) Merger Sub shall be merged with and
into StatSpin (the "MERGER"), (b) the separate existence of Merger Sub shall
cease and (c) StatSpin shall continue as the surviving corporation (sometimes
referred to herein as the "SURVIVING CORPORATION") and shall succeed to and
assume all of the rights and obligations of Merger Sub in accordance with the
Massachusetts Business Corporation Law. The Merger shall have the effects set
forth herein and in the applicable provisions of the Massachusetts Business
Corporation Law.
1.2 CLOSING. The closing of the Merger (the "CLOSING") shall take place
at the offices of Irell & Manella, counsel to IRIS, at 1800 Avenue of the Stars,
Suite 900, Los Angeles, California as soon as practicable after the satisfaction
or waiver of the
<PAGE>
conditions set forth in Section 6. (The date on which the Closing occurs is
hereinafter referred to as the "CLOSING DATE").
1.3 CONSUMMATION OF THE MERGER; EFFECTIVE TIME. As soon as practicable on
the Closing Date, the parties hereto shall consummate the Merger by executing
and filing articles of merger (the "ARTICLES OF MERGER") with the Secretary of
State of the Commonwealth of Massachusetts in such form as required by, and
executed in accordance with, the Massachusetts Business Corporation Law. The
Merger shall become effective (the "EFFECTIVE TIME") upon the filing of the
Articles of Merger.
1.4 ARTICLES OF ORGANIZATION; BY-LAWS. The Articles of Organization and
By-Laws of Merger Sub, as in effect immediately prior to the Effective Time and
as amended by the Articles of Merger, shall become the Articles of Organization
and By-Laws of the Surviving Corporation and thereafter shall continue in effect
until amended as provided therein and in the Massachusetts Business Corporation
Law.
1.5 DIRECTORS AND OFFICERS. The directors and officers of Merger Sub
immediately prior to the Effective Time shall become the directors and officers
of the Surviving Corporation and shall hold office from the Effective Time until
their respective successors are duly elected or appointed and qualified in the
manner provided in the By-Laws of the Surviving Corporation, or as otherwise
provided by law.
1.6 CONVERSION OF CAPITAL STOCK. At the Effective Time and subject to the
provisions of Sections 1.9 (Escrow of Shares) and 1.10 (Maximum Merger
Consideration), by virtue of the Merger and without any action on the part of
IRIS, StatSpin, Merger Sub or any stockholder of StatSpin:
1.6.1 CONVERSION OF OUTSTANDING STATSPIN STOCK. Each share of
StatSpin Common Stock issued and outstanding immediately prior to the Effective
Time, other than shares held by StatSpin as treasury stock and shares held by
persons exercising dissenters' rights ("DISSENTING SHARES"), shall be converted
into the right to receive 4.0950 shares of IRIS Common Stock (the "EXCHANGE
RATIO").
1.6.2 CANCELLATION OF STATSPIN TREASURY SHARES. Each Share held by
StatSpin as treasury stock immediately prior to the Effective Time shall be
cancelled and extinguished at the Effective Time without any conversion thereof
and no payment shall be made with respect thereto.
1.6.3 CONVERSION OF MERGER SUB STOCK. Each share of common stock,
$.01 par value per share, of Merger Sub issued and outstanding issued and
outstanding immediately prior to the Effective Time shall be converted into one
(1) share of common stock of the Surviving Corporation.
1.6.4 EXCHANGE OF CERTIFICATES; FRACTIONAL SHARES. As soon as
practicable after the Effective Time, each holder of an outstanding
certificate(s) that prior thereto represented a share of StatSpin Common Stock
shall surrender such certificate(s) to the
-2-
<PAGE>
transfer agent for IRIS, together with a duly executed letter of transmittal or
affidavit of loss and such other documents as may be reasonably requested by
IRIS or the transfer agent (including, without limitation, an indemnification
agreement with respect to lost certificates), and shall thereupon be entitled to
receive in exchange therefor a certificate or certificates representing the
number of whole shares of IRIS Common Stock into which the shares so surrendered
shall have been converted. No fractional shares shall be issued, but in lieu
thereof holders of certificates who would otherwise be entitled to receive a
fraction of a share of IRIS Common Stock shall be paid an amount in cash equal
to the value of such fraction of a share based upon the IRIS Stock Price. The
fractional share interests of each holder shall be aggregated so that no holder
receives cash in an amount equal to or greater than the value of one full share
of IRIS Common Stock. Until so surrendered, each certificate which, prior to
the Effective Time, represented shares of StatSpin Common Stock shall, from and
after the Effective Time, represent only the right to receive shares of IRIS
Common Stock and cash in lieu of any fractional interests. Neither IRIS, its
transfer agent, Merger Sub, StatSpin or the Surviving Corporation shall be
liable to any holder of such certificates for any cash or shares of IRIS Common
Stock properly paid to a public official pursuant to applicable abandoned
property, escheat or similar law.
1.7 CONVERSION OF STOCK APPRECIATION RIGHTS. At the Effective Time and
subject to (A) applicable federal and state withholding requirements, (B) the
provisions of Section 1.9 (Escrow of Shares) and (C) the provisions of
Section 1.10 (Maximum Merger Consideration), IRIS shall issue as satisfaction in
full for each StatSpin SAR issued and outstanding immediately prior to the
Effective Time the number of shares of IRIS Common Stock determined in
accordance with this Section 1.7.
1.7.1 UNCAPPED STATSPIN SAR'S. With respect to each holder of a
StatSpin SAR on the Effective Date which is not subject to an SAR Cap, IRIS
shall issue a number of shares of IRIS Common Stock equal to (A) the number of
shares of StatSpin Common Stock with respect to which such holder's StatSpin SAR
has vested MULTIPLIED BY (B) the difference between the StatSpin Stock Price and
the base price of such StatSpin SAR (i.e. the "spread") DIVIDED BY (C) the IRIS
Stock Price.
1.7.2 CAPPED STATSPIN SAR'S. With respect to each holder on the
Effective Date of a StatSpin SAR subject to an SAR Cap, IRIS shall issue a
number of shares of IRIS Common Stock equal to (A) the number of shares of
StatSpin Common Stock with respect to which such holder's StatSpin SAR has
vested MULTIPLIED BY (B) the difference between the SAR Cap and the base price
of such StatSpin SAR (i.e. the "spread") DIVIDED BY (C) the IRIS Stock Price.
1.7.3 EXCHANGE OF AGREEMENTS; FRACTIONAL SHARES. As soon as
practicable after the Effective Time, each holder of an outstanding agreement
that prior thereto represented a StatSpin SAR shall surrender such agreement to
the transfer agent for IRIS, together with a duly executed letter of transmittal
or affidavit of loss and such other documents as may be reasonably requested by
IRIS or the transfer agent (including, without limitation, an indemnification
agreement with respect to lost
-3-
<PAGE>
certificates), and shall thereupon, subject to applicable federal and state
withholding requirements, be entitled to receive in exchange therefor a
certificate or certificates representing the number of whole shares of IRIS
Common Stock into which the StatSpin SAR agreement so surrendered shall have
been converted. No fractional shares shall be issued, but in lieu thereof
holders of StatSpin SAR agreements who would otherwise be entitled to receive a
fraction of a share of IRIS Common Stock shall be paid an amount in cash equal
to the value of such fraction of a share based upon the IRIS Stock Price. The
fractional share interests of each holder shall be aggregated so that no holder
receives cash in an amount equal to or greater than the value of one full share
of IRIS Common Stock. Until so surrendered, each agreement which, prior to the
Effective Time, represented a StatSpin SAR shall, from and after the Effective
Time, represent only the right to receive shares of IRIS Common Stock and cash
in lieu of any fractional interests. Neither IRIS, its transfer agent, Merger
Sub, StatSpin or the Surviving Corporation shall be liable to any holder of such
StatSpin SAR for any cash or shares of IRIS Common Stock properly paid to a
public official pursuant to applicable abandoned property, escheat or similar
law.
1.8 ASSUMPTION OF WARRANTS AND STOCK OPTIONS. At the Effective Time and
subject to the provisions of Section 1.10 (Maximum Merger Consideration), IRIS
shall assume each outstanding warrant (a "STATSPIN WARRANT"), and each
outstanding option, whether vested or unvested, (a "STATSPIN OPTION"), to
purchase shares of StatSpin Common Stock. From and after the Effective Time,
each outstanding StatSpin Warrant and each outstanding StatSpin Option shall
entitle the holder to purchase shares of IRIS Common Stock on the same terms and
conditions as set forth in such StatSpin Warrant or StatSpin Option (including,
without limitation, any applicable vesting schedule), EXCEPT THAT (i) the holder
shall be entitled to purchase the number, rounded down to the nearest whole
integer, of full shares of IRIS Common Stock such holder would have been
entitled to receive pursuant to the Merger had such holder exercised such
StatSpin Warrant or StatSpin Option in full, including as to unvested shares,
immediately prior to the Effective Time, (ii) the price per share of IRIS Common
Stock shall be an amount, rounded up to the nearest whole cent, equal to (A) the
exercise price per share for the shares of StatSpin Common Stock otherwise
purchasable pursuant to the StatSpin Warrant or StatSpin Option DIVIDED BY
(B) the Exchange Ratio, and (iii) the registration rights of the holder shall be
as set forth in the Registration Rights Agreement which shall supersede any
registration rights previously associated with or contained in such holders
StatSpin Option or StatSpin Warrant. As soon as practicable after the Effective
Time, upon receipt by IRIS of a copy of such StatSpin Warrant or StatSpin
Option, IRIS issue and deliver to the holder thereof an originally signed
agreement evidencing the foregoing assumption of such StatSpin Warrant or
StatSpin Option by IRIS.
1.9 ESCROW OF SHARES. At the Closing, the holders of record of StatSpin
Common Stock at the Effective Time and the holders of record of StatSpin SAR's
at the Effective Time shall deposit in escrow ten percent (10%) of the aggregate
number of shares of IRIS Common Stock received by them in connection with the
Merger (the "ESCROWED SHARES"). For purposes of creating such escrow, each
holder of record of at the Effective Time of StatSpin Common Stock and each
holder of record at the Effective
-4-
<PAGE>
Time of StatSpin SAR's shall contribute a pro rata number of the shares of IRIS
Common Stock based on the number of shares of IRIS Common Stock to which all
such holders are entitled at the Effective Time. Subject to compliance with the
provisions of Sections 1.6.4 (Exchange of Stock Certificates) and 1.7.3
(Exchange of StatSpin SAR Agreements), as applicable, the Escrowed Shares shall
be released in accordance with the terms of the Escrow Agreement to the holders
of record at the Effective Time of StatSpin Common Stock and the holders or
record at the Effective Time of StatSpin SAR's pro rata based on the number of
shares of IRIS Common Stock to which each holder was entitled at the Effective
Time. The escrow shall be administered in accordance with the terms of the
Escrow Agreement. The parties agree that for federal income tax purposes, the
holders of record at the Effective Time of StatSpin Common Stock and the holders
of record at the Effective Time of StatSpin SAR's will own the Escrowed Shares
as of the Effective Time.
1.10 MAXIMUM MERGER CONSIDERATION. The parties acknowledge that the
Exchange Ratio was based on an exchange of $3,000,000 of IRIS Common Stock for
all of the outstanding StatSpin Common Stock, StatSpin SAR's, StatSpin Warrants
and StatSpin Options. Therefore, the parties agree that the maximum
consideration to be paid by IRIS (including IRIS Common Stock to be reserved for
issuance upon exercise of StatSpin Options and StatSpin Warrants assumed by
IRIS) pursuant to the Merger shall be limited to a number of shares of IRIS
Common Stock equal to $3,000,000 plus the aggregate exercise price of the
outstanding StatSpin Options and StatSpin Warrants divided by the IRIS Stock
Price. In the event that the outstanding StatSpin Common Stock, StatSpin SAR's,
StatSpin Warrants and StatSpin Options at the Effective Time is greater as set
forth on SCHEDULES 2.4(A) AND 2.4(B), the Exchange Ratio shall be
proportionately decreased. No adjustment shall be made in the aggregate
consideration to be paid in the Merger as a result of any cash proceeds received
by StatSpin pursuant to the exercise of currently outstanding StatSpin Warrants
or StatSpin Options.
1.11 TAKING OF NECESSARY ACTION; FURTHER ACTION. If, at any time after the
Effective Time, any such further action is necessary or desirable to carry out
the purposes of this Agreement and to vest the Surviving Corporation with full
right, title and possession to all assets, property, rights, privileges, powers
and franchises of StatSpin and Merger Sub, the officers and directors of
StatSpin and Merger Sub are fully authorized in the name of their respective
corporations or otherwise to take, and will take, all such lawful and necessary
action.
1.12 REGISTRATION RIGHTS. The shares of IRIS Common Stock issued to
holders of StatSpin Common Stock and holders of StatSpin SAR's in connection
with the Merger, and the shares of IRIS Common Stock issuable upon exercise to
holders of StatSpin Warrants and StatSpin Options assumed by IRIS in connection
with the Merger, shall have the registration rights set forth in the
Registration Rights Agreement.
1.13 LEGEND. Each certificate for IRIS Common Stock issued hereunder or
under any StatSpin Warrant or StatSpin Option assumed hereunder, and each
certificate
-5-
<PAGE>
issued in exchange or upon transfer of any thereof, shall be stamped or
otherwise imprinted with a legend in substantially the following form:
The securities represented by this certificate have not been
registered under the Securities Act of 1933, as amended, or qualified
under any applicable state securities laws and may not be transferred,
sold, assigned, pledged or otherwise disposed of unless (i) a
registration statement under the Securities Act of 1933, as amended,
shall have become effective with respect thereto and all applicable
qualifications under state securities laws have been obtained with
respect thereto, (ii) or a written opinion from counsel for the holder
reasonably satisfactory to the issuer has been obtained stating that
no such registration or qualification is required.
SECTION 2
REPRESENTATIONS AND WARRANTIES OF STATSPIN
As an inducement for IRIS to enter into this Agreement, StatSpin hereby
represents and warrants to IRIS that each of the following statements is true
and correct:
2.1 EXISTENCE AND RIGHTS. StatSpin (i) is a corporation duly organized,
validly existing and in good standing under the laws of the State of
Massachusetts, and (ii) has the corporate power and authority to own its
properties and to carry on its business as now conducted. StatSpin has no
interests, direct or indirect, in any partnership, joint venture, corporation or
other business entity. The copies of the Charter and By-Laws of StatSpin, which
have been previously delivered to IRIS, are complete and correct. StatSpin is
duly qualified and in good standing in each jurisdiction in which the character
of its business makes such qualification necessary except where the failure to
so qualify would not have a Material Adverse Effect on StatSpin.
2.2 AGREEMENTS AUTHORIZED. The execution, delivery and performance by
StatSpin of this Agreement, and any related agreements to which it is or will be
a party, have been duly authorized by all necessary corporate action, including,
without limitation, approval by the holders of a majority of the outstanding
shares of StatSpin Common Stock, and do not require StatSpin to provide or
obtain any notice to, or the consent or approval from, any governmental or other
regulatory authority or other person except the following:
(i) the filing of the Articles of Merger with the Secretary of State of
the Commonwealth of Massachusetts;
(ii) the consent of Citizens Bank of Massachusetts under the terms of the
Revolving Loan Agreement dated August 1995 (which consent will not be obtained
with the permission of IRIS based on StatSpin's representation that there are no
amounts
-6-
<PAGE>
currently outstanding thereunder and will not be any amounts outstanding
thereunder on the Closing Date);
(iii) the consent of the Massachusetts Technology Development Corporation
under the terms of an Amended and Restated 9% Subordinated Secured Promissory
Note dated February 17, 1995 (which consent will not be obtained with the
permission of IRIS based on StatSpin's representation the outstanding principal
amount thereof does not exceed $125,000);
(iv) the consent of holders of more than 50% of the aggregate principal
amount outstanding of the StatSpin's 12% Subordinated Notes dated March 13, 1992
(which consents will be obtained prior to Closing);
(v) the consent of each holder of a StatSpin Option (which consents will be
obtained prior to Closing); and
(vi) the consent of each holder of a StatSpin Warrant (which consents will
be obtained prior to Closing).
This Agreement, and any related agreements to which StatSpin is or will be a
party, have been (or will be) duly executed and delivered by StatSpin and are
(or upon execution and delivery will be) legal, valid and binding obligations of
StatSpin enforceable against StatSpin in accordance with their terms, subject to
bankruptcy, insolvency, reorganization, moratorium or other similar laws
affecting or relating to creditors rights generally and general principles of
equity.
2.3 NO CONFLICT. The execution, delivery and performance by StatSpin of
this Agreement and any related agreements will not (i) modify, breach or
constitute grounds for the occurrence or declaration of a default under or allow
another party a right to terminate (with or without notice or lapse of time or
both) any agreement, indenture, undertaking or other instrument to which
StatSpin is a party or by which it or any of its assets may be bound or affected
except for the agreements as to which StatSpin has disclosed under Section 2.2
with respect to which required consents will not be obtained, (ii) violate any
provision of law or any regulation or any order, judgement, or decree of any
court or other agency of government to which StatSpin is subject, (iii) violate
any provision of the Charter or By-Laws of StatSpin, or (iv) result in the
creation or imposition of (or the obligation to create or impose) any Claim on
any of StatSpin's properties except as disclosed in Section 2.2.
2.4 CAPITALIZATION. The authorized capital stock of StatSpin consists
solely of 300,000 shares of StatSpin Common Stock, of which 69,771 shares are
issued and outstanding. SCHEDULES 2.4(A) AND (B) set forth a complete and
accurate list of all outstanding shares of StatSpin Common Stock, StatSpin
Warrants, StatSpin Options and StatSpin SAR's, the holders thereof and the
material terms thereof. StatSpin has terminated its 1984 Incentive Stock Option
Plan and there are no stock options outstanding under such plan. StatSpin does
not hold any shares of StatSpin Common
-7-
<PAGE>
Stock in its treasury. Except as set forth SCHEDULES 2.4(A) AND (B), StatSpin
has no outstanding stock appreciation right, option, warrant, convertible debt,
subscription agreement, rights agreement or other commitment which either
(i) obligates StatSpin to issue, sell or transfer any shares of the capital
stock of StatSpin or any successor-in-interest, (ii) obligates StatSpin to
repurchase, redeem or otherwise acquire any outstanding shares of the capital
stock of StatSpin, or (iii) may be the basis for a claim by any person that such
person has an interest (contingent or otherwise) in the equity of StatSpin or
any successor-in-interest. All of the outstanding shares of the StatSpin Common
Stock are duly and validly issued, fully paid, non-assessable and not subject to
any preemptive rights, are owned of record by the persons in the amounts shown
in SCHEDULE 2.4(A), and to the best knowledge of StatSpin are free and clear of
all Claims (including, without limitation, stockholders agreements, voting
agreements and rights of first refusal) except as set forth on SCHEDULE 2.4(A).
2.5 FINANCIAL STATEMENTS. StatSpin has previously delivered to IRIS
correct and complete copies of (a) audited financial statements for each of
StatSpin's last three fiscal years, together with the notes thereto and the
unqualified independent auditors' reports of KPMG Peat Marwick thereon, and (b)
unaudited interim financial statements for the 6-month periods ended September
30, 1995 and 1994 (such audited and unaudited financial statements,
collectively, the "STATSPIN FINANCIAL STATEMENTS"). The StatSpin Financial
Statements (i) are correct and complete in all material respects (subject, in
the case of the unaudited StatSpin Financial Statements, to normal year-end
adjustments which are not expected to be material in amount and the absence of
footnotes), (ii) present fairly the financial position of StatSpin at such dates
and the results of the operations and cash flows of StatSpin for the periods
covered therein, (iii) are complete and correct in all material respects, and
(iv) have been prepared in accordance with generally accepted accounting
principles applied on a consistent basis.
2.6 NO MATERIAL CHANGES. Since September 30, 1995, StatSpin has conducted
its business only in the ordinary course consistent with past practice, and
there has not been:
(i) except as disclosed on ANY SCHEDULE to this Agreement, any
Material Adverse Effect, or any occurrence or event which could reasonably be
expected to have a Material Adverse Effect, on StatSpin;
(ii) any declaration or payment of any dividend or other distribution
on or in respect of any capital stock of StatSpin, or any direct or indirect
redemption, retirement, purchase or other acquisition of any capital stock of
StatSpin;
(iii) any increase, which is either not in the ordinary course of
business or is in excess of 5% in the aggregate or for any individual, in the
compensation by StatSpin to any of its directors, officers, employees,
consultants or agents, or any hiring of a director, officer, employee,
consultant or agent at a base compensation level in excess of $40,000 per annum,
or
-8-
<PAGE>
(iv) any transaction involving StatSpin and any Related Party.
2.7 UNDISCLOSED LIABILITIES. Except as set forth on SCHEDULE 2.7,
StatSpin has no obligations, indebtedness or liabilities (including without
limitation liabilities to current and former employees, including without
limitation such liabilities arising out of any benefit plan, health plan, dental
plan, long or short term disability plan, life insurance plan, or other similar
plan or policy of StatSpin), contingent or otherwise and whether or not such
liabilities would ordinarily be required under generally accepted accounting
principles to be accrued on a balance sheet or referred to in a footnote, other
than: (i) those disclosed or adequately reserved for on StatSpin's September 30,
1995, balance sheet; (ii) obligations, indebtedness or liabilities incurred
since September 30, 1995 in the ordinary course of business consistent with past
practice; or (iii) obligations and liabilities which do not exceed $30,000 in
the aggregate.
2.8 CONTINGENCIES. Except as set forth on SCHEDULE 2.8 or in the StatSpin
Financial Statements, (i) there are no express product warranties relating to
products manufactured or distributed by StatSpin; (ii) there is no litigation,
arbitration, administrative proceeding, audit request or, to the best knowledge
of StatSpin, investigation pending against StatSpin, its business or its assets;
(iii) StatSpin does not know of any threats of, or reasonable basis for, any
such litigation, arbitration, administrative proceeding or investigation, the
results of which could reasonably be expected to have a Material Adverse Effect
on StatSpin; (iv) neither the Food & Drug Administration ("FDA") nor any
comparable state agency has within the past six (6) years notified, or to the
best StatSpin's knowledge, intends to notify, StatSpin of any violation of the
Federal Food, Drug and Cosmetics Act, the regulations promulgated thereunder or
any comparable state laws or regulations; (v) StatSpin does not know of, and has
never received any notice of, any potential liability under the Comprehensive
Environmental Response, Compensation and Liability Act of 1980 or any comparable
state law or regulation; (vi) to the extent due on or before the date hereof,
StatSpin has paid all sales and use taxes arising out of the operation of its
business; and (vi) the StatSpin Financial Statements do not include and, under
generally accepted accounting principles applied on a consistent basis, are not
required to include, any reserves for liabilities relating to product warranties
on the products sold by it. StatSpin is not subject to any order, writ,
injunction or decree of any court or other governmental or regulatory authority.
2.9 REAL PROPERTY. StatSpin does not own or lease any real property other
than the 10,851 square feet of the premises located at 85 Morse Street, Norwood,
Massachusetts (the "PREMISES") which are leased by StatSpin pursuant to the
terms and conditions of that certain Commercial Lease by and between John E.
Reardon and Paul E. Reardon, on the one hand, and StatSpin, on the other hand,
dated February 15, 1990, as amended by that certain First Amendment to Agreement
of Lease dated April 1, 1995. StatSpin has previously delivered a true and
correct copy of such lease to IRIS, and StatSpin is not in default thereunder
which default could reasonable be expected to have a Material Adverse Effect on
StatSpin. To the best knowledge of StatSpin, such lease remains in full force
and effect without any default of the other party thereto.
-9-
<PAGE>
2.10 PERSONAL PROPERTY AND LEASEHOLD IMPROVEMENTS. StatSpin has the right
to use all personal property held by it or used in its business, and the
buildings, offices, and any other structures occupied by StatSpin, and all
computers, machinery, equipment and motor vehicles owned or used by StatSpin are
in the aggregate in good operating condition, except for ordinary wear and tear
and assets which are no longer in use, and are generally adequate and sufficient
for the operation of StatSpin's business as currently conducted.
2.11 RESTRICTIVE AGREEMENTS. Except as set forth on SCHEDULE 2.11, there
are no contracts, agreements or understandings to which StatSpin is a party or
under which StatSpin is bound that in any way preclude or substantially restrict
StatSpin from competing in any geographic area or business sector.
2.12 INTELLECTUAL PROPERTY. SCHEDULE 2.12 identifies all of the
Intellectual Property along with (if applicable) the registration numbers, dates
of issuance and names of the inventors or authors of such patents, marks, names
and registered copyrights and any other related information. Except as set
forth on SCHEDULE 2.12, StatSpin is the exclusive owner of all such Intellectual
Property free and clear of all Claims and is not a party to any license,
agreement or arrangement, whether as licensee, licensor or otherwise, with
respect to any such Intellectual Property. Except as set forth on SCHEDULE
2.12, (i) StatSpin has the unencumbered right and authority to use all of the
Intellectual Property; (ii) to the best knowledge of StatSpin, such use does not
conflict with, infringe on, or violate any rights of others; (iii) StatSpin is
not in default under any license relating to any of the Intellectual Property;
(iv) there have been no claims made against StatSpin asserting the invalidity,
abuse, misuse or unenforceability of any of its Intellectual Property, and, to
the best knowledge of StatSpin, there are no reasonable grounds for the same;
(v) StatSpin has not received a notice of conflict with the asserted rights of
others with respect to any Intellectual Property within the last three years;
and (vi) to the best knowledge of StatSpin, no person is violating or infringing
any of the Intellectual Property.
2.13 INVENTORY. StatSpin's inventory is of a quality saleable in the
normal course of business and contains quantities appropriate for normal
operations subject to inventory reserves reflected in the StatSpin Financial
Statements.
2.14 INSURANCE. StatSpin has in full force and effect the policies of
fire, liability, errors and omissions and other forms of insurance listed on
SCHEDULE 2.14, and the copies of such policies provided to IRIS are accurate and
complete. StatSpin reasonably believes that such policies are adequate in
amount and scope to cover all pending and reasonably anticipated product
liability claims against StatSpin. Furthermore, (i) StatSpin is not in default
in any material respect under any such policies and there is no material
inaccuracy in any application for such policies, (ii) StatSpin's activities and
operations have been conducted in a manner so as to conform in all material
respects to the applicable provisions of such policies, and (iii) StatSpin has
not received a notice of cancellation, non-renewal or premium increase with
respect to any such policy.
-10-
<PAGE>
2.15 CONTRACTS. SCHEDULE 2.15 correctly lists all contracts and
commitments, written and oral, to which StatSpin is a party or by which StatSpin
or any of its assets are bound, including all amendments, modifications and
waivers thereto (the "MATERIAL CONTRACTS"), which (i) relate to any Intellectual
Property, (ii) relate to any real property, (iii) restrict StatSpin's ability to
compete in any product line or in any geographic market, (iv) could reasonably
be expected to involve the payment or receipt by StatSpin of more than $30,000
in any 12-month period, (v) relate to the purchase, sale, repurchase, transfer,
registration, issuance or voting of StatSpin Common Stock, StatSpin Warrants or
StatSpin SAR's, (vi) relate to any indebtedness for borrowed money or any
guarantee thereof, (vii) create any lien on any of the assets of StatSpin or
(viii) involve any Related Party; PROVIDED, HOWEVER that Material Contracts
shall not include purchase orders or employment contracts. The copies of the
Material Contracts (including all amendments, modifications and waivers)
previously delivered to IRIS are complete and correct. Each of the Material
Contracts (including all amendments, modifications and waivers) (a) has been
duly authorized, executed and delivered by StatSpin and, to the best knowledge
of StatSpin, the other parties thereto, (b) to the best knowledge of StatSpin,
remains in full force and effect to the extent of its terms without any
amendment, modification or waiver not reflected in the Material Contracts
previously delivered to IRIS, (c) to the best knowledge of StatSpin, is binding
on the parties thereto in accordance with and to the extent of its terms and
applicable laws, subject to bankruptcy, insolvency, reorganization, moratorium
or other similar laws affecting or relating to creditors rights generally and
general principles of equity and (d) StatSpin has not received any notice
threatening or declaring, termination as a result of any alleged uncured breach
or default. StatSpin is not in default under any existing note, mortgage, or
other Material Contract, including, without limitation, (i) the 11% Subordinated
Notes dated April 30, 1991, (ii) the 12% Subordinated Notes dated March 13,
1992, (iii) the Amended and Restated 9% Subordinated Secured Note dated February
17, 1995 and (iv) the Revolving Loan Agreement dated August 1995 with Citizens
Bank.
2.16 ACQUISITION AGREEMENTS. Neither StatSpin nor, to the best knowledge
of StatSpin, any stockholder of StatSpin is or intends to be a party to any
agreement, written or oral, with any other person or entity concerning a merger,
consolidation, asset or stock acquisition, disposition or other business
acquisition or business combination transaction involving StatSpin.
2.17 BUSINESS RELATIONS. StatSpin has good commercial working
relationships with its customers, suppliers and distributors. StatSpin has not
received notice that any of its customers, suppliers or distributors intends to
terminate or alter its relationship with StatSpin except for terminations or
alterations which would not, in the aggregate, have a Material Adverse Effect on
StatSpin or the Surviving Corporation. StatSpin reasonably believes that the
Transactions will not adversely affect the relationship of StatSpin (including,
after the Effective Time, Surviving Corporation) with any of its suppliers or
distributors.
2.18 AFFILIATE TRANSACTIONS. Except as disclosed in the notes to the
StatSpin Financial Statements, to the best knowledge of StatSpin, no Related
Party of StatSpin
-11-
<PAGE>
(i) owns (other than ownership of less than one percent (1%) of the stock of a
publicly traded corporation), directly or indirectly, individually or
collectively, any interest in any corporation, partnership, firm, association or
sole proprietorship, which is either a competitor, potential competitor,
customer, supplier or distributor of StatSpin or has an existing contractual
relationship with StatSpin; or (ii) owes any money to or is owed any money by
StatSpin, other than indebtedness for compensation earned and not yet paid in
the ordinary course of business.
2.19 BENEFIT PLANS. SCHEDULE 2.19 sets forth all employee benefit plans,
funds, programs or arrangements (including but not limited to employee benefit
plans as defined in Section 3(3) of ERISA) which StatSpin has sponsored or
maintained, or to which it has been required to contribute ("BENEFIT PLANS").
StatSpin has previously delivered to IRIS complete and correct copies of all
Benefit Plan documents (including trust, investment management and custodial
agreements and insurance and annuity policies and contracts) and the most recent
IRS form 5500 Series filing and summary plan description, related to each
Benefit Plan. Except as otherwise described on SCHEDULE 2.19, (i) each Benefit
Plan has been operated in material conformity with its terms and applicable laws
(including but not limited to the Code and ERISA); (ii) all continuation
coverage under any group health plan provided by StatSpin or any entity under
common control or constituting an affiliated service group with StatSpin (within
the meaning of Section 414(b), (c), (m) or (o) of the Code) has been provided in
material conformity with the Code and ERISA; (iii) StatSpin has made all
contributions required to be made by it under any Benefit Plan for all plan
years ending before the Closing Date and has either made or accrued all such
contributions with respect to all periods commencing prior to the date hereof,
including without limitation all employee contributions and corresponding
matching contributions to the 401(k) Plan maintained by StatSpin; (iv) each
funded employee pension plan as defined in Section 3(2) of ERISA is qualified
under Section 401(a) of the Code, as amended by the Retirement Equity Act and
the Deficit Reduction Act of 1984, and nothing has occurred which has resulted
or is likely to result in the revocation of such qualification; (v) neither
StatSpin nor any entity under common control or constituting an affiliated
service group with StatSpin (within the meaning of Section 414(b), (c), (m) or
(o) of the Code) sponsors, maintains or is required to contribute to any defined
benefit pension plan (as defined in Section 3(35) of ERISA), is a party to or
has contributed to any multi-employer plan (as defined in Section 3(37) of
ERISA), has incurred any unsatisfied liability under Title IV of ERISA, or
assumed any liability under Section 4204 of ERISA; (vi) to the best knowledge of
StatSpin, no prohibited transaction (as defined in either Section 4975 of the
Code or Section 406 of ERISA) has occurred with respect to any Benefit Plan;
(vii) StatSpin has complied in all material respects with the reporting and
disclosure requirements under ERISA and the Code to the extent applicable to any
Benefit Plan; and (viii), to the best knowledge of StatSpin, no director or
officer of StatSpin, to the extent he or she is a fiduciary with respect to any
Benefit Plan, has breached any responsibility or obligation imposed upon
fiduciaries under Title I of ERISA or which would result in any claim being made
under, by or on behalf of any Benefit Plan and there has been no actual,
anticipated or threatened litigation, arbitration or governmental administrative
action concerning or involving any such Benefit Plan. StatSpin has, in all
summary plan
-12
<PAGE>
descriptions or other written employee communications relating to any employee
benefit plan (as defined in Section 3(3) of ERISA), reserved its rights to amend
or terminate the Benefit Plan to which the description or other communications
relates and has not represented otherwise in any such description or
communications, nor has StatSpin represented that any health or medical
insurance benefit is available to any employee after such employee's separation
from service with StatSpin except as provided in any disability plan, as
required by law or as disclosed on SCHEDULE 2.19.
2.20 ENVIRONMENTAL MATTERS. Except as disclosed on SCHEDULE 2.20, StatSpin
has complied in all material respects with, and is in material compliance with,
the provisions of all federal, state and local environmental, health and safety
laws, codes and ordinances, and all rules and regulations promulgated thereunder
pertaining to Hazardous Materials, waste, air emissions, water discharges, and
other environmental and health safety matters with respect to StatSpin's use or
occupation of the Premises. StatSpin has not generated, handled, treated,
stored, transported or disposed of any Hazardous Material other than in material
compliance with any applicable federal, state or local laws, codes, ordinances,
rules or regulations applicable to such activity. StatSpin has no liability for
damage to third parties or property or remediation of contaminated property
pursuant to CERCLA or similar state laws relating to the use, transportation,
storage or disposal of Hazardous Material, nor has StatSpin received notice of,
nor does StatSpin have reason to know of, any facts or circumstances which might
reasonably be expected to give rise to liability relating to the use,
transportation, storage, or disposal of Hazardous Materials, or which might
reasonably be expected to give rise to liability for employee exposure to
Hazardous Materials. StatSpin has disposed of, or arranged for the disposal of,
its solid and liquid wastes in compliance with applicable Hazardous Materials
laws. To the best of its knowledge, StatSpin has not disposed of, or arranged
for the disposal of, any waste or Hazardous Materials to any location which is
listed or proposed for listing under CERCLA, or on any similar state list, or
which is the subject of federal, state or local enforcement actions or other
investigations which may lead to liability on the part of IRIS or the Surviving
Corporation for site investigation or cleanup costs, remedial work, damages to
natural resources or for personal injury. To the best of its knowledge,
StatSpin does not lease any property located on a site which is listed or
proposed for listing under CERCLA or on any similar state list.
2.21 COMPLIANCE WITH LAWS. Except as specifically set forth on ANY
SCHEDULE to this Agreement, StatSpin is not in violation of any applicable law
or regulation, or of any judgment, order, decree or other requirement of any
court, tribunal or governmental body, or any agency or official acting in an
official capacity, the violation of which, individually or in the aggregate,
would reasonably be expected to have a Material Adverse Effect on StatSpin.
2.22 PERMITS. StatSpin has all Permits and Licenses required for the
ownership, use and operation of its property and assets, both real and personal,
and all other Permits and Licenses which are necessary or proper for the conduct
of its business. Except as set forth on SCHEDULE 2.22, each Permit and License
is presently valid and in full force and effect; no proceeding is pending or, to
the best knowledge of StatSpin,
-13
<PAGE>
threatened to revoke, limit or negate any such Permit or License; and no such
Permit or License has ever been revoked, limited or negated or been threatened
with such action. Immediately after the Effective Time, each Permit and License
will be valid and in full force and effect with respect to StatSpin. StatSpin
does not know, or have reason to know, of any facts or circumstances which would
reasonably be expected to prevent renewal of any of StatSpin's Permits or
Licenses after the Effective Time prior to their scheduled expiration or require
additional Permits or Licenses in order to operate its business as presently
operated. StatSpin is in compliance in all material respects with its Permits
and Licenses.
2.23 LABOR RELATIONS; EMPLOYEES. StatSpin has good relationships with its
employees and consultants. Except for satisfaction of the SAR's as expressly
provided in this Agreement, StatSpin has not made and is not obligated to make
any payments contingent on the Merger. StatSpin has generally not required its
employees and consultants to execute confidentiality, non-competition or
invention assignment agreements, but StatSpin reasonably believes that the
failure to obtain such agreements from its employees and consultants will not
have a Material Adverse Effect on StatSpin. StatSpin does not have any
employment, severance, change-of-control or similar agreements with any of its
employees other than (i) an Employment Agreement dated as of May 26, 1994 with
Thomas F. Kelley, a true and correct copy of which has been previously delivered
to IRIS and (ii) agreements evidencing the StatSpin SAR's listed on
SCHEDULE 2.4(B). StatSpin is not delinquent in payments to any of its employees
or consultants for any wages, salaries, commissions, benefits, bonuses or other
direct or indirect compensation for any services performed by him or her prior
to the date hereof or amounts required to be reimbursed to any of its employees
or consultants. Except as disclosed on SCHEDULE 2.8, there is no pending or (to
the best knowledge of StatSpin) threatened litigation by any employees or
consultants with respect to StatSpin, and there are no pending or (to the best
knowledge of StatSpin) threatened administrative actions or claims with respect
to StatSpin's relationship to any employee or consultant including without
limitation discrimination claims (whether for sex, age, race, religion, national
origin or any other reason). There is no unfair labor practice complaint
against StatSpin pending before the National Labor Relations Board or any
comparable state, local or foreign agency, and there is no labor strike,
dispute, slowdown or stoppage actually pending or, to the best knowledge of
StatSpin, threatened against or involving StatSpin. StatSpin is not a party to
nor is it subject to any collective bargaining agreement and none is currently
being negotiated, and StatSpin is not aware of any union organizing activities
in connection with StatSpin. StatSpin has no plans to terminate, and to the
best knowledge of StatSpin, no executive, salesperson or key employee or
consultant of StatSpin has any plans to terminate, the employment or consulting
relationship of any such person with StatSpin either prior to or after the
Effective Time.
2.24 TAXES. Except as disclosed on SCHEDULE 2.24, StatSpin has (i) timely
filed all returns for Taxes required to be filed on or before the date hereof or
has obtained extensions (without penalty or interest) of the deadline for
filing; (ii) paid or adequately reserved on its September 30, 1995 balance sheet
for all Taxes which may be owed by it as of such date; (iii) adequately reserved
for deferred Taxes in accordance with generally
-14-
<PAGE>
accepted accounting principles consistently applied; and (iv) duly withheld,
collected and paid over to the proper governmental authorities all Taxes and
assessments required to have been withheld or collected and paid over by
StatSpin, all as and to the extent prescribed by law. StatSpin has not been
advised of any deficiency claimed or proposed to be claimed against or relating
to StatSpin by any taxing authority which has not been paid, settled or
adequately reserved for on its September 30, 1995 balance sheet, and there are
no matters under discussion with any taxing authority which might reasonably
result in the assessment of additional amounts against or relating to StatSpin.
There are no liens for Taxes (other than for current Taxes not yet due and
payable) upon the assets of StatSpin. StatSpin has previously delivered to IRIS
complete and correct copies of all federal, state and local income tax returns
of or in respect of StatSpin for StatSpin's tax years ended March 31, 1995,
1994, 1993 and 1992. StatSpin is not a party to or bound by any tax indemnity,
tax sharing or tax allocation agreement. StatSpin has never been a member of an
affiliated group of corporations within the meaning of Section 1504 of the Code.
StatSpin has never been a party to any joint venture, partnership, or other
arrangement or contract which could be treated as a partnership for federal
income tax purposes.
2.25 POOLING MATTERS. Neither StatSpin nor any of its Affiliates has, to
the best knowledge of StatSpin based solely upon consultation with its
independent auditors, taken or agreed to take any action that would prevent IRIS
from accounting for the business combination to be effected by the Merger as a
pooling of interests under Opinion No. 16 of the Accounting Principles Board.
2.26 BOARD APPROVAL. The Board of Directors of StatSpin has (i) approved
the Merger, this Agreement and the Articles of Merger and (ii) recommended that
its stockholders approve the Merger, this Agreement and the Articles of Merger.
2.27 NO FINDER'S FEE. Neither StatSpin nor, to the best of its knowledge,
any of its stockholders, officers, directors, agents or employees have incurred
any liability to any broker, finder or agent for any brokerage fees, finder's
fees, commissions or similar amounts with respect to the Transactions.
2.28 DISCLOSURE. To the knowledge of StatSpin, the written information
delivered or made available by StatSpin or its representatives to IRIS or its
representatives in connection with the Transactions, taken as whole, does not
contain any untrue statement of a material fact, or omit to state any material
fact necessary in order to make the statements contained herein, in the light of
the circumstances under which it was made, not misleading, except where such
untrue statement or omission was corrected in subsequent information delivered
or made available by StatSpin or its representatives to IRIS or its
representatives.
2.29 OFFERING MEMORANDUM. None of the information provided by StatSpin for
inclusion in the Offering Memorandum will contain any untrue statement of a
material fact or omit to state any material fact required to be stated therein
or necessary in order
-15-
<PAGE>
to make the statements therein, in light of the circumstances under which they
are made, not misleading.
2.30 TRANSACTION EXPENSES. The fees and expenses incurred by StatSpin in
connection with the negotiation, preparation and execution of this Agreement and
any related agreement, and the consummation of the Transactions, will not exceed
$65,000 in the aggregate.
SECTION 3
REPRESENTATIONS AND WARRANTIES OF IRIS
As an inducement for StatSpin to enter into this Agreement, IRIS represents
and warrants that each of the following statements is complete and correct:
3.1 EXISTENCE AND RIGHTS. IRIS (i) is a corporation duly organized,
validly existing and in good standing under the laws of the State of Delaware
and (ii) has the corporate power and authority to own its properties and to
carry on its business as now conducted. The copies of the Certificates of
Incorporation and By-Laws of IRIS which have been previously delivered to
StatSpin are complete and correct.
3.2 AGREEMENTS AUTHORIZED. The execution, delivery and performance by
IRIS of this Agreement, and any related agreements to which it is or will be a
party, have been duly authorized by all necessary corporate action and do not
require IRIS to provide or obtain any notice to, or the consent or approval
from, any governmental or other regulatory authority or other person except the
American Stock Exchange. This Agreement, and any related agreements to which it
is or will be a party, has been duly executed and delivered by IRIS and is a
legal, valid and binding obligation of IRIS enforceable against IRIS in
accordance with its terms, subject to bankruptcy, insolvency, reorganization,
moratorium or other similar laws affecting or relating to creditors rights
generally and general principles of equity.
3.3 NO CONFLICT. The execution, delivery and performance by IRIS of this
Agreement and any related agreements will not (i) modify, breach or constitute
grounds for the occurrence or declaration of a default under or allow another
party a right to terminate (with or without notice or lapse of time or both) any
agreement, indenture, undertaking or other instrument to which IRIS is a party
or by which it or any of its assets may be bound or affected, (ii) violate any
provision of law or any regulation or any order, judgement, or decree of any
court or other agency of government to which IRIS is subject, (iii) violate any
provision of the Charter or By-Laws of IRIS, or (iv) result in the creation or
imposition of (or the obligation to create or impose) any Claim on any of the
properties of IRIS.
-16-
<PAGE>
3.4 IRIS SHARES. The shares of IRIS Common Stock, when issued in the
Merger in compliance with this Agreement, will be duly and validly issued, fully
paid and non-assessable.
3.5 IRIS SEC REPORTS. IRIS has previously furnished to StatSpin complete
and correct copies of the IRIS Annual Report on Form 10-K for the year ended
December 31, 1994, Proxy Statement dated April 29, 1995 and Quarterly Report on
Form 10-Q for the quarter ended September 30, 1995 (collectively, the "IRIS SEC
DOCUMENTS"). As of their respective filing dates, the IRIS SEC Documents
complied in all material respects with the requirements of the Exchange Act and
none of the IRIS SEC Documents contained any untrue statement of a material fact
or omitted to state a material fact required to be stated therein or necessary
to make the statements made therein, in light of the circumstances in which they
were made, not misleading, except to the extent corrected by a document
subsequently filed with the SEC. The financial statements of IRIS, including
the notes thereto, included in the IRIS SEC Documents (the "IRIS FINANCIAL
STATEMENTS") comply as to form in all material respects with applicable
accounting requirements and with the published rules and regulations of the SEC
with respect thereto, have been prepared in accordance with generally accepted
accounting principles consistently applied (except as may be indicated in the
notes thereto or, in the case of unaudited statements, as permitted by Form 10-Q
of the SEC), fairly present the consolidated financial position of IRIS at the
dates thereof and of its operations and cash flows for the periods then ended
(subject, in the case of unaudited statements, to normal, recurring audit
adjustments) and are complete and correct in all material respects. There has
been no change in IRIS accounting principles except as described in the notes to
the IRIS Financial Statements. IRIS has no material obligations other than (i)
those set forth in the IRIS Financial Statements and (ii) those not required to
be set forth in the IRIS Financial Statements under generally accepted
accounting principles.
3.6 NO MATERIAL CHANGES. Since September 30, 1995, there has not been any
Material Adverse Effect, or any occurrence or event which could reasonably be
expected to have a Material Adverse Effect, on IRIS which has not been disclosed
in the SEC Filings or the Offering Memorandum. The IRIS press release dated
November 15, 1995 announcing the development program with Poly U/A Systems, Inc.
and the completion of a related unit offering is true and correct in all
material respects.
3.7 DISCLOSURE. To the knowledge of IRIS, the written information
delivered or made available by IRIS or its representatives to StatSpin or its
representatives in connection with the Transactions, taken as a whole, does not
contain any untrue statement of a material fact, or omit to state any material
fact necessary in order to make the statements contained herein, in the light of
the circumstances under which it was made, not misleading, except where such
untrue statement or omission was corrected in subsequent information delivered
or made available by IRIS or its representatives to StatSpin or its
representatives.
-17-
<PAGE>
3.8 NO FINDER'S FEES. Neither IRIS nor any of its officers, directors,
agents or employees has incurred any liability to any broker, finder or agent
for any brokerage fees, finder's fees, commissions or similar amounts with
respect to the Transactions.
3.9 OPERATIONS OF MERGER SUB. Merger Sub will be a newly formed
Massachusetts corporation formed solely for the purpose of facilitating the
Merger and, except as otherwise described or contemplated in this Agreement,
will not have conducted any business operations prior to the Effective Time.
3.10 OFFERING MEMORANDUM. None of the information included by IRIS in the
Offering Memorandum will contain any untrue statement of a material fact or omit
to state any material fact required to be stated therein or necessary in order
to make the statements therein, in light of the circumstances under which they
are made, not misleading.
SECTION 4
COVENANTS OF STATSPIN
4.1 CONDUCT PRIOR TO EFFECTIVE TIME. StatSpin covenants that, between the
date of this Agreement and the Effective Time, unless IRIS shall otherwise
consent in writing in advance:
4.1.1 CAPITAL STOCK CHANGES; DIVIDENDS; REDEMPTIONS. Except for the
issuance of shares of StatSpin Common Stock upon the exercise of presently
outstanding StatSpin Warrants and StatSpin Options, StatSpin shall not issue or
sell any shares of its capital stock or other securities, acquire directly or
indirectly, by redemption or otherwise, any such capital stock, reclassify or
split-up any such capital stock, declare or pay any dividends thereon in cash,
securities or other property or make any other distribution with respect
thereto, or grant or enter into any options, warrants, calls or commitments of
any kind with respect thereto;
4.1.2 ORDINARY COURSE. StatSpin shall conduct its business only in
the ordinary and usual course consistent with past practice.
4.1.3 CERTAIN PERSONNEL. StatSpin shall use reasonable efforts to
prevent any change with respect to StatSpin's management, supervisory personnel
or sales personnel.
4.1.4 GOODWILL. StatSpin shall use reasonable efforts to preserve
the goodwill of customers, suppliers, distributors and others having business
relations with StatSpin.
4.1.5 INSURANCE. StatSpin shall use reasonable efforts to maintain
in full force and effect all policies of insurance with respect to StatSpin now
in effect (or secure
-18-
<PAGE>
comparable replacement policies in the event the insurer cancels or declines to
renew such policies) and shall give all notices and present all claims under all
such policies in a timely fashion.
4.1.6 SALE OR ACQUISITION OF ASSETS. StatSpin shall not Transfer or
acquire (whether through a purchase, merger or otherwise) any assets except
inventory sold in the ordinary course of business consistent with past practice
or capital assets acquired in accordance with Section 4.1.9.
4.1.7 INDEBTEDNESS. StatSpin shall not (i) borrow or agree to borrow
any funds or incur, assume, or guarantee, any obligation or liability (absolute
or contingent), which is not incurred in the ordinary course of business; or
(ii) pay, discharge or satisfy any claim, liability or obligation (absolute,
accrued, contingent or otherwise), other than the payment, discharge or
satisfaction in the ordinary course of business consistent with past practice of
liabilities or obligations reflected or reserved against in the StatSpin
Financial Statements or incurred after the dates thereof in the ordinary course
of business consistent with past practice.
4.1.8 RELATED PARTY TRANSACTIONS. StatSpin shall not effect any
transaction with any Related Party except as required under an existing
agreement or arrangement the terms of which have been previously disclosed to
IRIS, nor shall StatSpin enter into any new contract or arrangement with any
Related Party.
4.1.9 CAPITAL EXPENDITURES AND MATERIAL CONTRACTS. StatSpin shall
not (i) make any capital expenditures in excess of $10,000 individually or
$30,000 in the aggregate (other than the purchase of tooling as previously
discussed with IRIS which shall not be counted toward such dollar limits), (ii)
enter into, amend, terminate, renew or waive any provision of any Material
Contract or (iii) commit to any of the foregoing.
4.1.10 AMENDMENT OF CHARTER. StatSpin shall not amend its Charter or
By-laws except pursuant to the Articles of Merger or make any change in its
authorized or issued capital stock except pursuant to the exercise of the
outstanding StatSpin Warrants and StatSpin Options disclosed on SCHEDULE 2.4(A)
OR 2.4(B).
4.1.11 PRESERVATION OF ORGANIZATION. StatSpin shall use reasonable
efforts (i) to maintain at all times the status of StatSpin as a corporation
duly organized, validly existing, in good standing and duly qualified and
licensed to conduct its business as now being conducted in each of the
jurisdictions in which such business is now being conducted; (ii) to maintain in
effect all Permits and Licenses that are required for StatSpin to carry on its
business; and (iii) to preserve StatSpin's business organizations intact.
4.1.12 STANDARD OF CONDUCT. StatSpin shall operate in compliance
with all applicable laws.
-19-
<PAGE>
4.1.13 PROHIBITED DISCUSSIONS. StatSpin shall not shall solicit,
encourage or respond to any inquiries from any person or entity, or provide
information to, or conduct negotiations with, any other person or entity
concerning a sale of all or any part of the assets of StatSpin (except a sale of
assets of immaterial value in the ordinary course of StatSpin's business as
previously conducted), sale of stock, merger, consolidation, or other form of
business acquisition or business combination transaction involving StatSpin or
its capital stock. StatSpin shall also use reasonable efforts to prevent any of
its stockholders or agents from engaging in any of the foregoing activities.
StatSpin shall immediately (i) communicate to IRIS the substance of any inquiry
or proposal concerning any such transaction which may be received by it or, to
its knowledge, any of its stockholders or agents and (ii) reject any such
inquiry or proposal.
4.2 TRANSFERS OF STATSPIN EQUITY SECURITIES. Between the date of this
Agreement and the Effective Time, StatSpin shall use reasonable efforts to
prevent the Transfer any StatSpin Common Stock or other StatSpin securities.
4.3 CONSENTS. As promptly as practicable after the date of this
Agreement, StatSpin shall effect all filings, registrations and requests for
consent with, and use reasonable efforts to obtain all consents, authorizations,
approvals and declarations from, all third parties and government agencies
required under laws applicable to StatSpin or under contracts to which StatSpin
is a party for StatSpin and to consummate the Transactions. StatSpin shall use
reasonable efforts to obtain consents required, if any, in order to enable
Surviving Corporation to retain after the Effective Time all rights under
existing real and personal property leases and other contracts, without
modification. IRIS shall use reasonable efforts to assist StatSpin as
reasonably requested with all matters described above in this Section 4.3.
4.4 ACCESS. From the date hereof through the earlier of the Closing or
termination of this Agreement, StatSpin shall (i) permit IRIS and its authorized
representatives to have full access during normal business hours and under
reasonable conditions to any and all premises, properties, files, books,
records, documents and other information of StatSpin, (ii) provide IRIS and its
authorized representatives with all information which such parties reasonably
request concerning the foregoing matters, including without limitation, the
financial condition and results of operation of StatSpin, (iii) otherwise
reasonably cooperate with and assist IRIS and its authorized representatives in
connection with their investigation, (iv) upon the request of IRIS, deliver to
IRIS true and correct copies of any documents requested, and (v) provide IRIS
with access to and copies as requested of the work papers of KPMG Peat Marwick
compiled in connection with reviewing the financial statements of StatSpin. All
of the foregoing information shall be deemed confidential information and shall
be subject to the confidentiality provisions of the Letter of Intent.
4.5 STATSPIN STOCKHOLDER APPROVAL. StatSpin shall use its reasonable
efforts to secure as soon as practicable the approval (at a meeting or by
written consent) of all of its stockholders to the Merger, this Agreement and
the Articles of Merger. In
-20-
<PAGE>
connection therewith, StatSpin shall deliver to each of its stockholders, and to
each holder of a StatSpin SAR, StatSpin Warrant or StatSpin Option, a copy of
the Offering Memorandum prepared by IRIS, and StatSpin shall supply for
inclusion therein or incorporation by reference thereby such information
regarding StatSpin and the Transactions as may be reasonably requested by IRIS.
4.6 AFFILIATE AGREEMENTS. StatSpin and IRIS shall each use reasonable
efforts to obtain prior to the Closing an executed Affiliate Agreement from each
their respective Affiliates with respect to the Transfer of shares of IRIS
Common Stock. As soon as practicable after the date hereof, StatSpin shall
deliver to IRIS a list of names of those persons who are, in StatSpin's
reasonable judgment after consultation with legal counsel, Affiliates of
StatSpin. StatSpin shall provide IRIS such information and documents as IRIS
shall reasonably request for purposes of reviewing such list. IRIS shall be
entitled to place legends on the certificates evidencing any IRIS Common Stock
to be issued to StatSpin's Affiliates pursuant to the terms of this Agreement
and the Articles of Merger, and to issue appropriate stop transfer instructions
to the transfer agent for IRIS Common Stock, consistent with the terms of such
Affiliate Agreements, whether or not such Affiliate Agreements are actually
delivered to IRIS.
4.7 POOLING ACCOUNTING. StatSpin agrees not to knowingly take any action
that would adversely affect the ability of IRIS to treat the Merger as a pooling
of interests, and StatSpin agrees to take such action as may be reasonably
required to negate the impact of any past actions which would adversely impact
the ability of IRIS to treat the Merger as a pooling of interests.
4.8 REPRESENTATIONS AND WARRANTIES. StatSpin shall use reasonable efforts
to ensure that all of the representations and warranties of StatSpin contained
herein shall be true and correct from the date hereof through the Effective
Time.
4.9 LEGAL OPINION. StatSpin shall use its best efforts to cause Goodwin,
Procter & Hoar, counsel for StatSpin, to render an opinion at the Closing, dated
as of the Closing Date, in substantially the form attached hereto as EXHIBIT A.
4.10 SUPPLEMENTAL INFORMATION. From the date hereof through the Effective
Time, StatSpin shall deliver to IRIS immediately upon StatSpin's discovery or
access thereto, any information (i) as may be reasonably required to update the
information set forth on the Schedules hereto or (ii) that otherwise amends,
updates or conflicts with any of the matters discussed in the representations or
warranties set forth in Section 2.
4.11 ANNOUNCEMENTS. StatSpin shall not (before or after the Effective
Time) make any news release or other public announcement pertaining to the
Merger or any related transaction without the prior written consent of IRIS.
-21-
<PAGE>
SECTION 5
COVENANTS OF IRIS
5.1 REPRESENTATIONS TRUE. Until the Effective Time, IRIS will use its
best efforts to prevent the occurrence of any event which would cause any of its
representations and warranties set forth in this Agreement not to be true and
correct in any material respect.
5.2 CONSENTS. As promptly as practicable after the date of this
Agreement, IRIS shall effect all filings, registrations and requests for consent
with, and use reasonable efforts to obtain all consents, authorizations,
approvals and declarations from, all third parties and government agencies
required under laws applicable to IRIS or under contracts to which IRIS is a
party for IRIS or Merger Sub to consummate the Transactions other than the
filing of a registration statement under the Securities Act or any similar
filing with any state agency under the securities or "blue sky" laws of any
state. StatSpin shall use reasonable efforts to assist IRIS as reasonably
requested with all matters described above in this Section 5.2.
5.3 OFFERING MEMORANDUM. As soon as practicable, IRIS shall prepare and
deliver to StatSpin an Offering Memorandum (the "OFFERING MEMORANDUM") in form
and substance satisfactory to StatSpin and IRIS describing IRIS, StatSpin and
the Transactions.
5.4 LEGAL OPINION. IRIS shall use reasonable efforts to cause Irell &
Manella, counsel for IRIS and Merger Sub, to render an opinion at the Closing,
dated as of the Closing Date, in substantially the form attached hereto as
EXHIBIT B.
5.5 BENEFIT PLANS. IRIS agrees to provide employees of StatSpin with
credit for all prior service with StatSpin for purposes of vesting and
eligibility under any employee benefit plan, program or arrangement of IRIS and
to enroll the Statspin employees in such employee benefit plans, programs and
arrangements (including, without limitation, enrolling qualified employees in
the IRIS Key Employee Stock Purchase Program) as soon as practicable after the
Effective Time; PROVIDED, HOWEVER, IRIS shall continue StatSpin's current health
plan absent a significant increase in the cost thereof. Commencing three months
after the Effective Date, the senior management of the StatSpin will be eligible
for consideration for stock option awards under the 1994 IRIS Stock Option Plan
consistent with the Compensation Committee's general practices and policies.
5.6 INDEMNIFICATION OF STATSPIN DIRECTORS AND OFFICERS. The Articles of
Organization and Bylaws of the Surviving Corporation shall contain provisions
identical with respect to exculpation and indemnification to those set forth in
Article X of the Articles of Organization of StatSpin and Article V of the
Bylaws of StatSpin, respectively, which provisions shall not be amended,
repealed or otherwise modified for a period of six (6) years from the Effective
Time in any manner that would adversely
-22-
<PAGE>
affect the rights thereunder of the individuals who were directors or officers
of StatSpin at the Effective Time. The parties acknowledge that, in the event
of a merger of the Surviving Corporation with and into IRIS, the assumption by
IRIS of such indemnification obligations would not adversely affect the rights
of such directors and officers.
5.7 TAX COMPLIANCE, REPORTING AND OTHER ACTIONS. The parties acknowledge
that the Merger is intended to qualify as a reorganization within the meaning of
Section 368(a) of the Code. Accordingly, IRIS shall comply with, and shall
cause Merger Sub and the Surviving Corporation to comply with, the reporting
requirements set forth in Treasury Regulation Section 1.368-3 applicable to them
with respect to the Merger Acquisition, and none of them shall make any election
or take any reporting or other position inconsistent with the treatment of the
Merger as a reorganization within the meaning of Section 368(a) of the Code
except as required by law. Further, IRIS, Merger Sub and/or the Surviving
Corporation shall not take any action, or fail to take any action, which would
disqualify the Merger as a tax free reorganization under Section 368(a) of the
Code. Without limiting the foregoing, IRIS shall cause the Surviving
Corporation to satisfy the "continuity of business enterprise" requirement as
provided in Section 1.368-(1)(d) of the Treasury Regulations, and IRIS will not
transfer the stock, and the Surviving Corporation will not transfer the assets,
of the Surviving Corporation in a manner which would disqualify the Merger as a
tax free reorganization under Section 368(a) of the Code.
5.8 APPOINTMENT OF MR. KELLEY TO IRIS BOARD. Promptly upon consummation
of the Merger, IRIS shall appoint Thomas F. Kelley to the IRIS Board of
Directors as a Class 3 Director and thereafter nominate Mr. Kelley for
reelection at the 1996 Annual Meeting of the IRIS stockholders.
SECTION 6
CONDITIONS PRECEDENT
6.1 CONDITIONS PRECEDENT TO OBLIGATIONS OF IRIS. The obligations of IRIS
to consummate the Closing and effect the Merger are subject to the satisfaction
or waiver, prior to or at the Closing, of each of the following conditions
precedent:
6.1.1 ACCURACY OF REPRESENTATIONS AND WARRANTIES. The
representations and warranties of StatSpin contained in this Agreement or in any
certificate or document delivered to IRIS pursuant hereto shall be true and
correct on and as of the Closing Date as though made at and as of that date
(except where such representation and warranty is made as of a date specifically
set forth therein), and StatSpin shall have delivered to IRIS a certificate to
that effect.
6.1.2 COMPLIANCE WITH COVENANTS. StatSpin shall have in all material
respects performed and complied with all terms, agreements, covenants and
conditions of
-23-
<PAGE>
this Agreement to be performed or complied with by them at the Closing Date, and
StatSpin shall have delivered to IRIS certificates to that effect.
6.1.3 NONCOMPETITION AGREEMENT. Thomas F. Kelley, StatSpin's largest
stockholder, shall have executed and delivered to IRIS the Noncompetition
Agreement.
6.1.4 ESCROW AGREEMENT. Each holder of StatSpin Common Stock or a
StatSpin SAR shall have executed and delivered to IRIS the Escrow Agreement.
6.1.5 POOLING MATTERS. (i) Each Affiliate of StatSpin shall have
executed and delivered to IRIS an Affiliate Agreement; (ii) each Affiliate of
IRIS shall have executed and delivered to IRIS an Affiliate Agreement; (iii)
IRIS shall have been advised by Coopers & Lybrand, its independent auditors,
that the Merger will qualify as a "pooling of interests" under Opinion No. 16 of
the Accounting Principles Board; and (iv) Coopers & Lybrand shall have been
advised by KPMG, StatSpin's independent auditors, that StatSpin qualifies as a
"poolable entity" under Opinion No. 16 of the Accounting Principles Board.
6.1.6 REGISTRATION RIGHTS AGREEMENTS. Each holder of StatSpin Common
Stock, a StatSpin Warrant, a StatSpin Option or a StatSpin SAR shall have
executed and delivered to IRIS the Registration Rights Agreement.
6.1.7 SECURITYHOLDER REPRESENTATION LETTERS. Each holder of StatSpin
Common Stock, a StatSpin Warrant, a StatSpin Option or a StatSpin SAR shall have
executed and delivered to IRIS a Securityholder Representation Letter.
6.1.8 CONSENTS OBTAINED; FILINGS. StatSpin shall have obtained all
consents and approvals from, and shall have completed all declarations, filings
and registrations with, government agencies and private third parties that are
required for the execution, delivery and performance of this Agreement by
StatSpin, except for such consents, approvals, declarations, filings, and
registrations the failure of which to have so obtained or made will not have a
Material Adverse Effect on StatSpin.
6.1.9 NO MATERIAL ADVERSE EFFECT. There shall have been no Material
Adverse Effect, or any occurrence or event which could reasonably be expected to
have a Material Adverse Effect, on StatSpin.
6.1.10 LEGAL ACTIONS OR PROCEEDINGS. No legal action or proceeding
shall have been instituted or overtly threatened by any governmental agency
seeking to restrain, prohibit, invalidate or otherwise affect the consummation
of the Transactions, and no legal action or proceeding shall have been
instituted or overtly threatened by any private party seeking material monetary
awards from IRIS or Merger Sub in connection with the Transactions, or from
StatSpin whether or not in connection with the Transactions.
-24-
<PAGE>
6.1.11 ALL PROCEEDINGS TO BE SATISFACTORY. All corporate and other
proceedings to be taken by StatSpin in connection with the Transactions and all
documents incident thereto shall be reasonably satisfactory in form and
substance to IRIS and its counsel, and IRIS and said counsel shall have received
all such certified or other copies of such documents as it may reasonably
request.
6.1.12 OPINION OF COUNSEL FOR STATSPIN. IRIS shall have received the
favorable opinion of Goodwin, Proctor & Hoar, counsel to StatSpin, dated the
Closing Date, in substantially the form attached as EXHIBIT A.
6.1.13 IRIS EMPLOYEE ACKNOWLEDGMENT FORM. Each person employed by
StatSpin immediately prior to the Effective Time shall have executed and
delivered to IRIS a copy of the Employee Acknowledgement Form currently used by
IRIS.
6.1.14 DISSENTING SHARES. The number of Dissenting Shares shall not
constitute more than two percent (2%) of the outstanding shares of StatSpin
Common Stock.
6.2 CONDITIONS PRECEDENT TO OBLIGATIONS OF STATSPIN. The obligations of
StatSpin to consummate the Closing and effect the Merger are subject to the
satisfaction or waiver, prior to or at the Closing, of the following conditions
precedent:
6.2.1 ACCURACY OF REPRESENTATIONS AND WARRANTIES. The
representations and warranties of IRIS contained in this Agreement or in any
certificate or document delivered to StatSpin pursuant hereto shall be true and
correct on and as of the Closing Date as though made at and as of that date
(except where such representation and warranty is made as of a date specifically
set forth therein), and IRIS shall have delivered to StatSpin a certificate to
such effect.
6.2.2 COMPLIANCE WITH COVENANTS. IRIS and Merger Sub shall in all
material respects have performed and complied with all terms, agreements,
covenants and conditions of this Agreement to be performed or complied with by
it at the Closing Date, and IRIS shall have delivered to StatSpin a certificate
to that effect.
6.2.3 CONSENTS OBTAINED; FILINGS. IRIS shall have obtained all
consents and approvals from, and shall have completed all declarations, filings
and registrations with, government agencies and private third parties that are
required for the execution, delivery and performance of this Agreement by IRIS
and Merger Sub, except for such consents, approvals, declarations, filings, and
registrations the failure of which to have so obtained or made will not have a
Material Adverse Effect on IRIS.
6.2.4 AMEX LISTING. The American Stock Exchange shall have approved
for listing, subject only to official notice of issuance, the shares of IRIS
Common Stock issuable upon consummation of the Merger.
-25-
<PAGE>
6.2.5 EMPLOYMENT AGREEMENT. Thomas F. Kelley and either IRIS or the
Surviving Corporation shall have entered into a mutually acceptable employment
agreement which shall supersede Mr. Kelley's current employment agreement with
StatSpin.
6.2.6 NO MATERIAL ADVERSE EFFECT. There shall have been no Material
Adverse Effect, and no occurrence or event which could reasonably be expected to
result in a Material Adverse Effect, on IRIS.
6.2.7 ALL PROCEEDINGS TO BE SATISFACTORY. All corporate and other
proceedings to be taken by IRIS or Merger Sub in connection with the
Transactions and all documents incident thereto shall be reasonably satisfactory
in form and substance to StatSpin and its counsel, and StatSpin and said counsel
shall have received all such certified or other copies of such documents as they
may reasonably request.
6.2.8 OPINION OF COUNSEL FOR IRIS. StatSpin shall have received the
favorable opinion of Irell & Manella, counsel for IRIS and Merger Sub, dated the
Closing Date, substantially in the form attached as EXHIBIT B.
6.2.9 LEGAL ACTIONS OR PROCEEDINGS. No legal action or proceeding
shall have been instituted or overtly threatened by any governmental agency
seeking to restrain, prohibit, invalidate or otherwise affect the consummation
of the Transactions, and no legal action or proceeding shall have been
instituted or overtly threatened by any private party seeking material monetary
awards from StatSpin or its stockholders in connection with the Transactions.
6.2.10 REGISTRATION RIGHTS AGREEMENTS. IRIS shall have executed and
delivered the Registration Rights Agreement to the Stockholder Representative.
6.2.11 MINIMUM IRIS STOCK PRICE. The IRIS Stock Price shall be at
least $6.50.
6.2.12 ESCROW AGREEMENT. IRIS shall have executed and delivered the
Escrow Agreement to the Stockholder Representative.
SECTION 7
INDEMNIFICATION
7.1 INDEMNIFICATION OF IRIS. StatSpin, prior to the Effective Time, and
the StatSpin Stockholders, after the Effective Time, shall indemnify and hold
harmless IRIS, Merger Sub, the Surviving Corporation and their respective
officers, directors, employees and agents from and against the full amount of
Losses arising out of or resulting from a breach of any representation, warranty
or covenant made by StatSpin in this Agreement; PROVIDED, HOWEVER, that the
StatSpin Stockholders shall be liable to IRIS
-26-
<PAGE>
under this Section 7.1 only if the Merger is consummated and only to the extent
of the Escrowed Shares held in escrow pursuant to the Escrow Agreement, and the
Escrowed Shares shall be IRIS sole and exclusive remedy under this Section 7.1
against the StatSpin Stockholders.
7.2 INDEMNIFICATION OF STATSPIN AND THE STATSPIN STOCKHOLDERS. IRIS shall
indemnify and hold harmless StatSpin and its officers, directors, employees and
agents, prior to the Effective Time, and the StatSpin Stockholders, after the
Effective Time, from and against the full amount of Losses arising out of or
resulting from a breach of any representation, warranty or covenant made by IRIS
in this Agreement; PROVIDED, HOWEVER, that IRIS shall be liable to the StatSpin
Stockholders under this Section 7.2 only if the Merger is consummated.
7.3 SURVIVAL OF REPRESENTATIONS AND WARRANTIES. The representations and
warranties in this Agreement shall survive until the first (1st) anniversary of
the Closing Date, and, subject to the provisions of the Escrow Agreement
relating to Contingent Claims (as defined therein), no party may seek indemnity
under this Section 7 or any other recovery or remedy for any Loss under this
Agreement at any time after such anniversary.
7.4 DEDUCTIBLE AMOUNT. Notwithstanding the foregoing, neither IRIS, on
the one hand, nor StatSpin and the StatSpin Stockholders, on the other hand,
shall be required to indemnify the other under the terms of this Agreement
unless and until the aggregate amount of the Losses of the other exceeds
$30,000, in which case such indemnification obligations shall apply to all
Losses in excess of such amount.
7.5 EFFECT OF DISCLOSURES. The representations and warranties in this
Agreement shall remain in full force and effect regardless of any disclosures
made to or investigations made by a party; PROVIDED, HOWEVER, that the
Indemnifying Party shall have no indemnification obligation hereunder with
respect to any breach of a representation or warranty to the extent that the
Indemnifying Party proves that it did not have knowledge of such breach but the
Indemnified Party did have knowledge of such breach prior to the date hereof.
7.6 PROCEDURES FOR INDEMNIFICATION. If any claim is asserted or any
action or proceeding is brought in respect of which indemnity may be sought, the
Indemnified Party will promptly notify the Indemnifying Party in writing of such
asserted claim or the institution of such action or proceeding; PROVIDED,
HOWEVER, that the Indemnified Party's failure to so notify the Indemnifying
Party will not relieve the Indemnifying Party from any liability it might
otherwise have on account of this indemnity, except to the extent that the
Indemnifying Party has been materially prejudiced by such failure to notify.
The Indemnifying Party shall undertake full responsibility for the defense of
any Third-Party Claim which, if successful, would result in an obligation of
indemnity under this Section 7. The Indemnifying Party may contest or settle
any such claim on such terms as the Indemnifying Party may choose, PROVIDED that
the Indemnifying Party will not have the right, without the Indemnified Party's
prior written consent, to settle any
-27-
<PAGE>
such claim if such settlement (i) arises from or is part of any criminal action,
suit or proceeding, (ii) contains a stipulation to, confession of judgement with
respect to, or admission or acknowledgement of, any liability or wrongdoing on
the part of the Indemnified Party, (iii) relates to any Tax matters,
(iv) provides for injunctive relief, or other relief or finding other than money
damages, which is binding on the Indemnified Party, or (v) does not contain an
unconditional release of the Indemnified Party. Such defense will be conducted
by reputable attorneys retained by the Indemnifying Party at the Indemnifying
Party's cost and expense, but the Indemnified Party will have the right to
participate in such proceedings and to be separately represented by attorneys of
its own choosing. The Indemnified Party will be responsible for the costs of
such separate representation unless the Indemnified Party will have reasonably
concluded that the interests of the Indemnified Party and the Indemnifying Party
in the action conflict in such a manner and to such an extent as to make
advisable, consistent with applicable standards of professional responsibility,
the retention of separate counsel for the Indemnified Party, in which case the
Indemnifying Party will pay for one (but not more than one) separate counsel
chosen by the Indemnified Party.
7.7 FAILURE TO ASSUME DEFENSE. In the event that the Indemnifying Party,
by the 30th day after receipt of notice of any asserted claim (or, if earlier,
by the tenth day preceding the day on which an answer or other pleading must be
served in order to prevent judgment by default in favor of the person asserting
such claim), fails to assume the defense of such claim, the Indemnified Party
will (upon further notice to the Indemnifying Party) have the right to undertake
the defense, compromise or settlement of such claim on behalf of and for the
account and risk of the Indemnifying Party, subject to the right of the
Indemnifying Party to assume the defense of such claim at any time prior to
settlement, compromise or final determination thereof. The result of any such
defense, compromise or settlement executed by the Indemnified Party in good
faith shall be binding upon the Indemnifying Party with respect to its
obligations of indemnity under this Section 7.
7.8 COOPERATION. The Indemnifying Party and the Indemnified Party shall
cooperate in determining the validity of any Third-Party Claim or Tax claim for
any Loss for which a claim of indemnification may be made hereunder. Each party
shall also use all reasonable efforts to minimize all Losses.
7.9 STOCKHOLDER REPRESENTATIVE. The Stockholder Representative is hereby
appointed as agent and representative on behalf of the StatSpin Stockholders
with respect to any indemnification claims made hereunder and shall have full
authority to accept all notices, and consent to all settlements, on behalf of
the StatSpin Stockholders with respect to such claims. IRIS shall, by delivery
of written notice to the Stockholder Representative but otherwise in accordance
with the applicable notice requirements, be deemed to have satisfied any
requirement to deliver notice hereunder or under the Escrow Agreement to the
StatSpin Stockholders or any subset thereof.
-28-
<PAGE>
SECTION 8
TERMINATION
This Agreement may be terminated at any time on or prior to the Closing:
8.1 INJUNCTION. By StatSpin or IRIS if any court of competent
jurisdiction in the United States shall have issued an order (other than a
temporary restraining order), decree or ruling or taken any other action
restraining, enjoining or otherwise prohibiting the Transactions and such order,
decree, ruling or other action shall have become final and non-appealable.
8.2 MUTUAL AGREEMENT. By mutual agreement of StatSpin and IRIS.
8.3 TERMINATION DATE. By StatSpin or IRIS if the Closing shall not have
occurred on or before February 15, 1996, provided that the right to terminate
this Agreement pursuant to this Section 8.3 shall not be available to a party
who has materially breached any representation, warranty or covenant of this
Agreement.
8.4 MATERIAL BREACH. By StatSpin upon a material breach of any
representation, warranty or covenant of this Agreement by IRIS, and by IRIS upon
a material breach of any representation, warranty or covenant of this Agreement
by StatSpin, but only if such breach remains uncured for a period of ten (10)
days after receipt of written notice of such breach from the nonbreaching party.
8.5 EFFECTS OF TERMINATION. If this Agreement is terminated pursuant to
this Section 8, all obligations of the parties hereunder shall terminate without
liability of any party to any other party except the obligations of the parties
under Section 10.3 (Expenses), Section 10.10 (Governing Law;
Jurisdiction), Section 10.11 (Attorneys' Fees), Section 10.14 (Arbitration) and
the confidentiality provisions of the Letter of Intent (including, without
limitation, the confidentiality obligations thereunder). Nothing contained in
this Section 8.5 shall relieve any party of liability for any breach of this
Agreement which occurred prior to the date of termination of this Agreement.
8.6 RIGHTS TO PROCEED. Notwithstanding anything contained in this
Agreement to the contrary, if any of the conditions specified in Section 6.1
have not been satisfied, IRIS shall have the right to proceed with the
Transactions without waiving any of its rights hereunder arising out of the
breach of any representation, warranty or covenant herein; and if any of the
conditions specified in Section 6.2 not been satisfied, StatSpin shall have the
right to proceed with the Transactions without waiving any of its rights
hereunder.
-29-
<PAGE>
SECTION 9
DEFINITIONS
The following terms shall have the meanings set forth below:
"AFFILIATE" shall mean an "affiliate" within the meaning of Rule 145 of the
Rules and Regulations promulgated under the Securities Act and requirements for
a pooling of interests under Opinion No. 16 of the Accounting Principles Board.
"ARTICLES OF MERGER" shall have the meaning set forth in Section 1.3.
"BENEFIT PLANS" shall have the meaning set forth in Section 2.19.
"CLAIMS" shall mean any and all liens, mortgages, charges, claims,
liabilities, options, debts, security interests, secured claims, and other
encumbrances of any kind or nature whatsoever, whether or not contingent,
liquidated, disputed or known.
"CLOSING" and "CLOSING DATE" shall have the respective meanings set forth
in Section 1.2.
"CODE" shall mean the Internal Revenue Code of 1986, as amended.
"DISSENTING SHARES" shall have the meaning set forth in Section 1.6.1.
"EFFECTIVE DATE" shall mean the date on which the Effective Time falls.
"EFFECTIVE TIME" shall have the meaning set forth in Section 1.3.
"ERISA" shall mean the Employee Retirement Income Security Act of 1974, as
amended.
"ESCROW AGREEMENT" shall mean an Escrow Agreement, dated the Closing Date,
in substantially the form of EXHIBIT G.
"EXCHANGE RATIO" shall have the meaning set forth in Section 1.6.1.
"ESCROWED SHARES" shall have the meaning set forth in Section 1.9.
"FDA" shall have the meaning set forth in Section 2.8.
"HAZARDOUS MATERIAL" shall mean (i) any substance defined as "hazardous" in
the Comprehensive Environmental Response, Compensation and Liability Act of 1980
("CERCLA"); (ii) any substance or matter which results in liability to any
person or entity from discharge of or exposure to such substance or matter under
any statutory, regulatory or common law theory; (iii) any substance or matter
which becomes subject to
-30-
<PAGE>
a federal, state or local agency order or requirement for removal, treatment or
remediation; (iv) crude oil or any fraction thereof, and (v) any material
defined as "hazardous" under Massachusetts law.
"INDEMNIFIED PARTY" shall mean, with respect to any Loss or alleged Loss,
the party seeking indemnity hereunder.
"INDEMNIFYING PARTY" shall mean, with respect to any Loss or alleged Loss,
the party from whom indemnity is being sought hereunder.
"INTELLECTUAL PROPERTY" shall mean all patents, pending patents,
trademarks, service marks, trade names, trade secrets and registered copyrights
presently used by StatSpin in the conduct of its business.
"IRIS" shall mean International Remote Imaging Systems, Inc., a Delaware
Corporation.
"IRIS COMMON STOCK" shall mean the common stock, $.01 par value per share,
of IRIS.
"IRIS FINANCIAL STATEMENTS" shall have the meaning set forth in
Section 3.5.
"IRIS SEC DOCUMENTS" shall have the meaning set forth in Section 3.5.
"IRIS STOCK PRICE" shall mean $7.58 per share of IRIS Common Stock,
which represents the average closing price of a share of IRIS Common Stock on
the American Stock Exchange for the 10-day period ending on the third
business day preceding the date of this Agreement.
"LETTER OF INTENT" shall mean the letter from IRIS to StatSpin dated
October 27, 1995 confirming their mutual intention that IRIS acquire all of the
outstanding capital stock of StatSpin.
"LOSSES" shall mean any and all costs and expenses (including, without
limitation, reasonable attorneys' fees and expenses and court costs incident to
any suit, action, investigation or other proceedings), damages and losses, net
of any insurance proceeds or tax benefits received with respect thereto.
"MASSACHUSETTS BUSINESS CORPORATION LAW" shall mean the Business
Corporation Law of the Commonwealth of Massachusetts, Chapter 156B of the
General Laws of Massachusetts, as amended.
"MATERIAL ADVERSE EFFECT" shall mean, with respect to any party hereto, a
material adverse effect on the financial condition, results of operations,
properties, assets, liabilities, business or, to the best of such party's
knowledge, prospects of such party and, in the case of StatSpin, the Surviving
Corporation after the Effective Time.
-31-
<PAGE>
"MATERIAL CONTRACT" shall have the meaning set forth in Section 2.15.
"MERGER" shall have the meaning set forth in Section 1.1.
"MERGER SUB" shall mean Statspin Acquisition Corporation, a Massachusetts
corporation and wholly-owned subsidiary of IRIS.
"NONCOMPETITION AGREEMENT" shall mean a Noncompetition Agreement, dated the
Closing Date, in substantially the form of EXHIBIT C.
"OFFERING MEMORANDUM" shall have the meaning set forth in Section 5.3.
"PERMITS AND LICENSES" shall mean any and all federal, state and local
governmental permits, licenses, consents, approvals and authorizations, the loss
or violation of which would have a Material Adverse Effect on StatSpin,
including, without limitation, any required product marketing approvals and
manufacturing certifications from the FDA.
"PREMISES" shall have the meaning set forth in Section 2.9.
"REGISTRATION RIGHTS AGREEMENT" shall mean a Registration Rights
Agreements, dated the Closing Date, by and among IRIS and the holders of
StatSpin Common Stock, StatSpin Warrants, StatSpin Options and StatSpin SAR's in
substantially form of EXHIBIT E.
"RELATED PARTY" shall mean any stockholder, director or officer StatSpin,
any other person or entity that controls StatSpin, or any family member of any
of the foregoing.
"SAR CAP" shall mean, with respect to any StatSpin SAR held by certain
former employees of StatSpin, the fair market value per share of StatSpin Common
Stock on the date of such former employee's termination, determined in
accordance with the terms of such StatSpin SAR and set forth on SCHEDULE 2.4(B).
"SEC" shall mean the Securities and Exchange Commission.
"SECURITIES ACT" shall mean the Securities Act of 1933, as amended.
"SECURITYHOLDER REPRESENTATION LETTER" shall mean a representation letter,
dated the Closing Date, in substantially the form attached at EXHIBIT F.
"STATSPIN" shall mean Norfolk Scientific, Inc., a Massachusetts corporation
doing business as "StatSpin Technologies."
"STATSPIN COMMON STOCK" shall mean the common stock, $1.00 par value per
share, of StatSpin.
-32-
<PAGE>
"STATSPIN FINANCIAL STATEMENTS" shall have the meaning set forth in
Section 2.5.
"STATSPIN OPTION" shall have the meaning set forth in Section 1.8.
"STATSPIN SAR" shall mean a stock appreciation right granted by StatSpin to
an employee of StatSpin.
"STATSPIN STOCKHOLDERS" shall mean the holders of record at the Effective
Time of StatSpin Common Stock and the holders of record at the Effective Time of
StatSpin SAR's.
"STATSPIN STOCK PRICE" shall mean the value of a share of StatSpin Common
Stock determined on a fully-diluted basis, which the parties agree is $31.04 per
share of StatSpin Common Stock based upon the capitalization set forth in
SCHEDULES 2.4(A) AND 2.4(B).
"STATSPIN WARRANT" shall have the meaning set forth in Section 1.8.
"STOCKHOLDER REPRESENTATIVE" shall mean Thomas F. Kelley, the individual
appointed as agent and representative pursuant to the Escrow Agreement for the
holders of record at the Effective Time of StatSpin Common Stock and StatSpin
SAR's.
"SURVIVING CORPORATION" shall have the meaning set forth in Section 1.1.
"TAX OR TAXES" shall mean any and all federal, state, local, foreign and
other net income, gross income, gross receipts, sales, use, ad valorem,
transfer, franchise, profits, license, lease, service, service use, withholding,
payroll, employment, excise, severance, stamp, occupation, premium, property,
windfall profits, customs, duties or other taxes, fees, assessments or charges
of any kind whatever, together with any interest and any penalties, additions to
tax or additional amounts with respect thereto.
"THIRD-PARTY CLAIM" shall mean a claim brought by a third party for which
indemnification is sought pursuant to Section 7.
"TRANSACTIONS" shall mean the transactions contemplated by this Agreement.
"TRANSFER" shall mean any sale, transfer, assignment, hypothecation,
encumbrance or other disposition, whether voluntary or involuntary or whether by
gift, bequest or otherwise.
-33-
<PAGE>
SECTION 10
MISCELLANEOUS
10.1 ENTIRE AGREEMENT; MODIFICATIONS. This Agreement and any documents
referred to herein or executed contemporaneously herewith constitute the
parties' entire agreement with respect to the subject matter hereof and
supersede all agreements, representations, warranties, statements, promises and
understandings, whether oral or written, with respect to the subject matter
hereof; PROVIDED, HOWEVER, that the paragraphs of the Letter of Intent which are
expressly designated as binding shall remain in full force and effect. This
Agreement may not be amended, altered or modified except by a writing signed by
the parties.
10.2 MEANING OF "KNOWLEDGE". Whenever a representation or warranty is
stated to be based on the "KNOWLEDGE" of a party, such phrase refers to whether
any director or senior officer (i.e. an officer with a title at least equal to
vice president) of such party has actual knowledge of the matter involved. The
phrase "BEST KNOWLEDGE" shall refer to the "knowledge" of such directors or
officers after reasonable inquiry to the extent prudent under the circumstances.
10.3 EXPENSES. Except as set forth in Section 8.5, whether or not the
Transactions are consummated, none of the parties hereto shall have any
obligation to pay any of the fees and expenses of any other party incident to
the negotiation, preparation and execution of this Agreement or any related
agreements, including the fees and expenses of counsel, accountants, investment
bankers and other experts.
10.4 WAIVERS. StatSpin may by written notice to IRIS, or IRIS may, by
written notice to the StatSpin, (a) extend the time for the performance of any
of the obligations or other actions of the other parties under this Agreement;
(b) waive any inaccuracies in the representations or warranties of the other
parties contained in this Agreement or in any document delivered pursuant to
this Agreement; (c) waive compliance with any of the conditions or covenants of
the other parties contained in this Agreement; or (d) waive performance of any
of the obligations of the other parties under this Agreement. With regard to
any power, remedy or right provided herein or otherwise available to any party
hereunder, (i) no waiver or extension of time will be effective unless expressly
contained in a writing signed by the waiving party or its representative, and
(ii) no alteration, modification or impairment will be implied by reason of any
previous waiver, extension of time, delay or omission in exercise or other
indulgence.
10.5 COOPERATION. Each party hereto agrees, both before and after the
Effective Time, to execute any and all further documents and writings and to
perform such other actions which may be or become necessary or expedient to
effectuate and carry out this Agreement.
10.6 THIRD-PARTY BENEFITS. None of the provisions of this Agreement will
be for the benefit of, or enforceable by, any third-party beneficiary; PROVIDED,
HOWEVER that
-34-
<PAGE>
(i) the holders of StatSpin Common Stock shall be third-party beneficiaries of
Sections 1.6.4 (Exchange of Certificates), 3 (Representations and Warranties of
IRIS), 5.7 (Tax Compliance and Reporting) and 7.2 (Indemnification of StatSpin
and StatSpin Stockholders), (ii) the holders of StatSpin Warrants shall be
third-party beneficiaries of Sections 1.8 (Assumption of Warrants and Stock
Options) and 3 (Representations and Warranties of IRIS), (iii) the holders of
StatSpin Options shall be third-party beneficiaries of Sections 1.8 (Assumption
of Warrants and Stock Options) and 3 (Representations and Warranties of IRIS),
(iv) the holders of StatSpin SAR's shall be third-party beneficiaries of
Sections 1.7.3 (Exchange of StatSpin SAR Agreements) and 3 (Representations and
Warranties of IRIS), (v) the directors and officers of StatSpin at the Effective
Time shall be third-party beneficiaries of the provisions of Section 5.6
(Indemnification of Directors and Officers) and (vi) the employees of StatSpin
shall be third-party beneficiaries of Section 5.5 (Benefit Plans).
10.7 SUCCESSORS AND ASSIGNS. This Agreement shall inure to the benefit of
and be binding upon the parties hereto and their respective successors and
permitted assigns. None of the parties may assign any of his or its rights
under this Agreement without the prior written consent of the others.
10.8 REMEDIES NOT EXCLUSIVE. Subject to Section 10.14 ("Arbitration"), no
remedy conferred by any of the specific provisions of this Agreement is intended
to be exclusive of any other remedy, and each and every remedy will be
cumulative and will be in addition to every other remedy given hereunder or now
or hereafter existing at law or in equity or by statute or otherwise. The
election of any one or more remedies will not constitute a waiver of the right
to pursue other available remedies.
10.9 NOTICES. All notices under this Agreement will be in writing and will
be delivered by personal service or facsimile or certified mail (or, if
certified mail is not available, then by first class mail), postage prepaid, to
such address as may be designated from time to time by the relevant party, and
which will initially be as set forth below. Any notice sent by certified mail
will be deemed to have been given three (3) days after the date on which it is
mailed. All other notices will be deemed given when received. No objection may
be made to the manner of delivery of any notice actually received in writing by
an authorized agent of a party. Notices will be addressed as follows or to such
other address as the party to whom the same is directed will have specified in
conformity with the foregoing:
(a) If to IRIS:
International Remote Imaging Systems, Inc.
9162 Eton Avenue
Chatsworth, California 91311
Attn: Fred H. Deindoerfer
Chairman of the Board and President
Telephone: (818) 709-1244
Facsimile: (818) 700-9661
-35-
<PAGE>
With a copy to:
Irell & Manella
1800 Avenue of the Stars, Suite 900
Los Angeles, CA 90067
Attn: Theodore E. Guth, Esq.
Telephone: (310) 277-1010
Facsimile: (310) 204-7199
(b) If to StatSpin:
Norfolk Scientific, Inc.
c/o StatSpin Technologies
85 Morse Street
Norwood, Massachusetts 02062
Attn: Thomas F. Kelley, Ph.D.
Chairman of the Board and President
Telephone: (617) 551-0100
Facsimile: (617) 551-0036
With a copy to:
Goodwin, Procter & Hoar
Exchange Place
Boston, Massachusetts 02109
Attn: John R. LeClaire, Esq.
Telephone: (617) 570-1144
Facsimile: (617) 523-1231
10.10 GOVERNING LAW; CONSENT TO JURISDICTION. This Agreement has been
negotiated and entered into in the State of California, and all questions with
respect to the Agreement and the rights and liabilities of the parties under
this Agreement shall be governed by, and construed and enforced in accordance
with, the laws of the State of California without regard to the conflict of laws
rules of the State of California or any other jurisdiction. Subject to
Section 10.14 ("Arbitration"), any litigation between the parties that arises
from or relates to this Agreement shall be conducted exclusively in Los Angeles,
California. Each party (i) irrevocably consents to the exclusive jurisdiction
of the Los Angeles Superior Court and the Federal District Court for the Central
District of California (or their successor courts) for all purposes in
connection with any litigation that arises from or relates to this Agreement,
(ii) agrees that any litigation arising from or relating to this Agreement shall
be instituted and prosecuted only in the such courts, (iii) waives any rights it
may have to personal service of summons, complaint, or other process in
connection therewith, and (iv) agrees that service may be made by registered or
certified mail addressed to such party sent to the addresses designated from
time to time in accordance with Section 10.9.
-36-
<PAGE>
10.11 ATTORNEYS' FEES. Should any litigation or arbitration be
commenced (including any proceedings in a bankruptcy court) between the parties
hereto or their representatives concerning any provision of this Agreement or
the rights and duties of any person or entity hereunder, the party or parties
prevailing in such proceeding shall be entitled, in addition to such other
relief as may be granted, to the attorneys' fees and court costs incurred by
reason of such litigation or arbitration.
10.12 HEADINGS. The Section headings in this Agreement are inserted
only as a matter of convenience, and in no way define, limit, or extend or
interpret the scope of this Agreement or of any particular Section.
10.13 SEVERABILITY. The validity, legality or enforceability of the
remainder of this Agreement shall not be affected even if one or more of the
provisions of this Agreement shall be held to be invalid, illegal or
unenforceable in any respect. To the extent permitted by applicable law, the
parties hereby waive any provision of law that would render any provision hereof
prohibited or unenforceable in any respect.
10.14 ARBITRATION AS EXCLUSIVE REMEDY. Subject to the proviso in
Section 7.1 (Indemnification of IRIS) and except for actions seeking injunctive
relief, which may be brought before any court having jurisdiction, any claim
arising out of or relating to (i) this Agreement, including, but not limited to,
its validity, interpretation, enforceability or breach, or (ii) the relationship
between the parties (including its commencement and termination) which are not
settled by agreement between the parties, shall be settled by arbitration
conducted exclusively in Los Angeles, California before a board of three
arbitrators, one selected by each party, and the third by the two persons so
selected, all in accordance with the Commercial Arbitration Rules of the
American Arbitration Association ("AAA") then in effect. The notice of intent
to arbitrate shall name one arbitrator, and the party(ies) receiving the notice
shall name the second arbitrator within 15 days or the moving party may select
the second arbitrator from a list supplied by the AAA. In the event that these
two arbitrators cannot agree upon a third arbitrator within 15 days, then the
third arbitrator shall be selected from the list provided by the AAA with the
parties striking names in order with the party striking first to be determined
by the flip of a coin. The parties hereby consent to the in personam
jurisdiction of the Superior Court of the State of California for purposes of
confirming any such award and entering judgment thereon. In any arbitration
proceedings hereunder, (a) all testimony of witnesses shall be taken under oath;
(b) discovery will be allowed under the provisions of Section 1283.05 of the
California Code of Civil Procedure, as presently in force, which are
incorporated herein; (c) upon conclusion of any arbitration, the arbitrators
shall render findings of fact and conclusions of law in a written opinion
setting forth the basis and reasons for any decision reached and deliver such
documents to each party to this Agreement along with a signed copy of the award
in accordance with Section 1283.6 of the California Code of Civil Procedure; and
(d) the rules of evidence as then applicable to civil actions under California
law shall be applied in the arbitration. Each party agrees that the arbitration
provisions of this Agreement are its exclusive remedy and expressly waives any
right to seek redress in another forum. Each party shall bear the fees of the
arbitrator appointed by it, and the fees of
-37-
<PAGE>
the neutral arbitrators shall be borne equally by each party during the
arbitration, but the fees of all arbitrators shall be borne by the losing party.
10.15 AGREEMENT NEGOTIATED. The parties hereto are sophisticated and
have consulted legal counsel with respect to this transaction. As a
consequence, the parties do not believe that the presumptions of California
Civil Code Section 1654 relating to the interpretation of contracts against the
drafter of any particular clause should be applied in this case and therefore
waive its effects.
10.16 COUNTERPARTS. This Agreement may be executed simultaneously in
two or more counterparts, each of which shall be deemed an original, but all of
which together shall constitute one and the same instrument.
*** [NEXT PAGE IS SIGNATURE PAGE] ***
-38-
<PAGE>
SIGNATURE PAGE TO AGREEMENT AND PLAN OF MERGER
IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be
duly executed, as of the day and year first above written.
"IRIS"
INTERNATIONAL REMOTE IMAGING SYSTEMS, INC.
By: /s/ Fred H. Deindoerfer
---------------------------------------
Name: Fred H. Deindoerfer
------------------------------------
Title: Chairman of the Board and President
-----------------------------------
"MERGER SUB"
STATSPIN ACQUISITION CORPORATION
By: /s/ Fred H. Deindoerfer
---------------------------------------
Name: Fred H. Deindoerfer
------------------------------------
Title: Chairman of the Board and President
-----------------------------------
"STATSPIN"
NORFOLK SCIENTIFIC, INC.
By: /s/ Thomas F. Kelley
---------------------------------------
Name: Thomas F. Kelley
------------------------------------
Title: President
-----------------------------------
<PAGE>
CONSENT OF INDEPENDENT AUDITORS
The Board of Directors
Norfolk Scientific, Inc.:
We consent to the inclusion of (i) our report dated May 26, 1995, with
respect to the balance sheets of Norfolk Scientific, Inc. as of March 31,
1995 and 1994, and the related statements of income and accumulated deficit
and cash flows for the years then ended and (ii) our report dated May 27,
1994, except as to note 7 which is as of February 17, 1995, and note 5 which
is as of March 16, 1995, with respect to the balance sheets of Norfolk
Scientific, Inc. as of March 31, 1994 and 1993, and the related statements of
operations and accumulated deficit and cash flows for the years then ended,
which reports appear in the Form 8-K of International Remote Imaging Systems,
Inc. dated February 16, 1996.
KPMG Peat Marwick LLP
Boston, Massachusetts
February 15, 1996
<PAGE>
NORFOLK SCIENTIFIC, INC.
D/B/A STATSPIN TECHNOLOGIES
Financial Statements
March 31, 1995 and 1994
(With Independent Auditors' Report Thereon)
<PAGE>
[KPMG PEAT MARWICK LLP LETTERHEAD]
INDEPENDENT AUDITORS' REPORT
The Board of Directors
Norfolk Scientific, Inc.:
We have audited the accompanying balance sheets of Norfolk Scientific, Inc.
as of March 31, 1995 and 1994, and the related statements of income and
accumulated deficit, and cash flows for the years then ended. These
financial statements are the responsibility of the Company's management. Our
responsibility is to express an opinion on these financial statements based
on our audits.
We conducted our audits in accordance with generally accepted auditing
standards. Those standards require that we plan and perform the audit to
obtain reasonable assurance about whether the financial statements are free
of material misstatement. An audit includes examining, on a test basis,
evidence supporting the amounts and disclosures in the financial statements.
An audit also includes assessing the accounting principles used and
significant estimates made by management, as well as evaluating the overall
financial statement presentation. We believe that our audits provide a
reasonable basis for our opinion.
In our opinion, the financial statements referred to above present fairly, in
all material respects, the financial position of Norfolk Scientific, Inc. at
March 31, 1995 and 1994, and the results of its operations and its cash
flows for the years then ended, in conformity with generally accepted
accounting principles.
KPMG Peat Marwick LLP
May 26, 1995
<PAGE>
NORFOLK SCIENTIFIC, INC.
Balance Sheets
March 31, 1995 and 1994
<TABLE>
<CAPTION>
ASSETS (note 5) 1995 1994
---- ----
<S> <C> <C>
Current assets:
Cash (note 3) $ 167,100 283,202
Accounts receivable, trade, less allowance for doubtful accounts
of $54,242 in 1995 and $58,748 in 1994 (note 12) 374,135 456,344
Inventories (note 4) 461,858 680,915
Prepaid expenses 10,987 13,677
----------- ----------
Total current assets 1,014,080 1,434,138
----------- ----------
Property and equipment:
Manufacturing equipment 412,599 409,104
Furniture and fixtures 75,236 76,613
----------- ----------
487,835 485,717
Less accumulated depreciation 392,278 327,681
----------- ----------
Net property and equipment 95,557 158,036
----------- ----------
Other assets, net 44,166 43,912
----------- ----------
$ 1,153,803 1,636,086
----------- ----------
----------- ----------
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Note payable to bank (note 5) $ - 160,000
Current portion of subordinated notes payable to stockholders
(note 6) 50,324 25,164
Current portion of subordinated notes payable to MTDC (note 7) 55,553 200,000
Accounts payable, trade 175,336 379,114
Accrued expenses 148,805 200,295
Deferred revenue - 6,650
State income taxes payable 1,768 1,768
----------- ----------
Total current liabilities 431,786 972,991
----------- ----------
Subordinated notes payable to stockholders, less current maturities
(note 6) 150,000 177,258
Subordinated notes payable to MTDC, less current maturities (note 7) 111,107 173,605
----------- ----------
Total liabilities 261,107 350,863
----------- ----------
Stockholders' equity (notes 6, 7 and 8):
Common stock, $1 par value. Authorized 300,000 shares;
issued and outstanding 69,771 shares 69,771 69,771
Additional paid-in capital 732,211 732,211
Accumulated deficit (341,072) (489,750)
----------- ----------
Total stockholders' equity 460,910 312,232
----------- ----------
Commitments and contingencies (notes 9 and 11)
$ 1,153,803 1,636,086
----------- ----------
----------- ----------
</TABLE>
See accompanying notes to financial statements.
<PAGE>
NORFOLK SCIENTIFIC, INC.
Statements of Income and Accumulated Deficit
Years ended March 31, 1995 and 1994
<TABLE>
<CAPTION>
1995 1994
---- ----
<S> <C> <C>
Net sales (note 12) $ 2,918,212 3,450,251
Cost of sales 1,824,913 2,038,342
----------- ----------
Gross profit 1,093,299 1,411,909
----------- ----------
Operating expenses:
Research and development 194,313 413,016
Selling, general, and administrative 682,426 879,237
----------- ----------
Total operating expenses 876,739 1,292,253
----------- ----------
Income from operations 216,560 119,656
----------- ----------
Interest income (expense):
Interest income 5,812 5,224
Interest expense (73,238) (81,899)
----------- ----------
Interest expense, net (67,426) (76,675)
----------- ----------
Income before income taxes 149,134 42,981
Provision for income taxes (note 10) 456 906
----------- ----------
Net income 148,678 42,075
Accumulated deficit, beginning of year (489,750) (531,825)
----------- ----------
Accumulated deficit, end of year $ (341,072) (489,750)
----------- ----------
----------- ----------
</TABLE>
See accompanying notes to financial statements.
<PAGE>
NORFOLK SCIENTIFIC, INC.
Statements of Cash Flows
Years ended March 31, 1995 and 1994
<TABLE>
<CAPTION>
1995 1994
---- ----
<S> <C> <C>
Cash flows from operating activities:
Net income $ 148,678 42,075
Adjustments to reconcile net income to net cash provided
by operating activities:
Depreciation and amortization 74,285 89,559
Changes in assets and liabilities:
Accounts receivable, net 82,209 (38,624)
Inventories, net 219,057 (170,156)
Prepaid expenses 2,690 114
Accounts payable, trade (203,778) 248,909
Accrued expenses (51,490) 21,864
Deferred revenue (6,650) (33,350)
Customer deposits - (34,625)
State income taxes payable - (2,844)
---------- ---------
Net cash provided by operating activities 265,001 122,922
---------- ---------
Cash flows from investing activities:
Additions to property and equipment (2,118) (93,273)
Increase in other assets, net (9,942) (15,226)
---------- ---------
Net cash used by investing activities (12,060) (108,499)
---------- ---------
Cash flows from financing activities:
Net (decrease) increase in line of credit borrowings (160,000) 65,046
Repayments on notes payable to stockholders (2,098) (23,078)
Proceeds on notes payable to MTDC 166,660 -
Repayments on notes payable to MTDC (373,605) (76,395)
---------- ---------
Net cash used by financing activities (369,043) (34,427)
---------- ---------
Net decrease in cash (116,102) (20,004)
Cash, beginning of year 283,202 303,206
---------- ---------
Cash, end of year $ 167,100 283,202
---------- ---------
---------- ---------
Supplemental disclosures of cash flow information:
Cash paid during the year for interest $ 118,379 76,384
---------- ---------
---------- ---------
Cash paid during the year for taxes $ 456 3,750
---------- ---------
---------- ---------
</TABLE>
See accompanying notes to financial statements.
<PAGE>
NORFOLK SCIENTIFIC, INC.
Notes to Financial Statements
March 31, 1995 and 1994
(1) NATURE OF BUSINESS
Norfolk Scientific, Inc. (d/b/a StatSpin Technologies) (the "Company") was
incorporated on June 11, 1984, as a successor to Kelley, Newhouse &
Company, a partnership. The Company purchased assets and rights from its
predecessor to engage in the development, manufacture, and sale of
medical and laboratory equipment and supplies.
(2) SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
(A) INVENTORIES
Inventories are stated at the lower of cost or market, cost being determined
using the first-in, first-out (FIFO) method.
(B) PROPERTY AND EQUIPMENT
Property and equipment is stated at cost. Depreciation is provided using an
accelerated method over the estimated useful lives of the respective
assets.
(C) OTHER ASSETS, NET
Other assets consist principally of patents, stated at cost, net of
accumulated amortization. The cost of patents is amortized using the
straight-line method over the estimated useful lives (five years) of the
respective patents.
(D) INCOME TAXES
The Financial Accounting Standards Board has issued Statement 109,
"Accounting for Income Taxes." Statement 109 requires a change from the
deferred method required under APB Opinion 11 to the asset and liability
method. Under the deferred method, annual income tax expense is matched
with pretax accounting income by providing deferred taxes at current tax
rates for timing differences between the determination of net income for
financial reporting and tax purposes. The objective of the asset and
liability method is to establish deferred tax assets and liabilities for
the temporary differences between the financial reporting basis and the
tax basis of the Company's assets and liabilities at enacted tax rates
expected to be in effect when such amounts are to be realized or settled.
Under Statement 109, the effect on deferred tax assets and liabilities
of change in tax rates is recognized in income in the period that includes
the enactment date.
Effective April 1, 1993, the Company adopted Statement 109. The cumulative
effect of the change in the method of accounting for income taxes is not
material and therefore is not presented separately in the accompanying
statements of operations and accumulated deficit for the year ended
March 31, 1995. Prior years' financial statements have not been restated
to apply the provisions of Statement 109.
(E) RECLASSIFICATIONS
Certain reclassifications have been made to the fiscal 1994 financial
statements to conform to the fiscal 1995 presentation.
(Continued)
<PAGE>
2
NORFOLK SCIENTIFIC, INC.
Notes to Financial Statements
(3) RESTRICTED CASH
The entire cash balance as of March 31, 1994 was restricted. This cash
was available for operating uses with the approval of Company's
board of directors and the Massachusetts Technology Development
Corporation ("MTDC"). During 1995, this restriction was removed in
conjunction with the Company's restructuring of the debt due
MTDC (see note 7).
(4) INVENTORIES
Inventories consist of the following at March 31:
<TABLE>
<CAPTION>
1995 1994
---- ----
<S> <C> <C>
Raw materials $ 367,852 584,454
Work in process 114,500 98,496
Finished goods 49,127 78,754
--------- --------
531,479 761,704
Less: Reserve for obsolescence (69,621) (80,789)
--------- --------
$ 461,858 680,915
--------- --------
--------- --------
</TABLE>
(5) NOTE PAYABLE TO BANK
Note payable to bank consists of borrowings under a $300,000 line of
credit, expiring on September 30, 1995, that is secured by all of the
assets of the Company. Under the line of credit the Company can borrow
up to 75% of any of its accounts receivable balances, excluding those
that have invoices outstanding for over 90 days. Interest is payable
monthly at the bank's base rate plus 1.5% (9.5% and 8.25% at March 31,
1995 and 1994, respectively). The Company had $0 and $160,000 of
outstanding borrowings at March 31, 1995 and 1994, respectively.
(6) RELATED PARTY TRANSACTIONS
Notes payable to stockholders totaling $200,324 and $202,422 at March 31,
1995 and 1994, respectively, consist of unsecured subordinated
borrowings with interest payable monthly. The notes consist of $75,500
in borrowings dated April 30, 1991, payable in 36 monthly installments
of approximately $2,097, commencing May 1, 1993, and $150,000 in
borrowings dated March 13, 1992, due on March 13, 1997. Interest on
the $75,500 note accrues on the unpaid principal balance at 11% and is
payable monthly in arrears on the first day of each month starting
November 1, 1991, with the first six months' interest having been
deferred and paid in equal installments over the eighteen-month period
commencing November 1, 1991. Interest on the $150,000 note accrues on
the unpaid principal balance at 12% and is payable monthly in arrears
on the first day of each month starting November 1, 1993, with the
first eighteen months' interest having been deferred and paid in equal
installments over the eighteen-month period commencing November 1,
1993. Interest expense for notes payable to stockholders for the years
ended March 31, 1995 and 1994, amounted to $23,536 and $25,899,
respectively.
(Continued)
<PAGE>
3
NORFOLK SCIENTIFIC, INC.
Notes to Financial Statements
Under the notes payable agreements, the Company is required to comply
with various restrictive covenants. As of March 31, 1995, the Company
was not in compliance with certain covenants. The Company has
constructively received a waiver of such defaults as outlined in the
note agreements as of March 31, 1995.
In addition, 4,651 and 23,332 warrants, respectively, were issued to
related parties in connection with the April 30, 1991 and March 13,
1992 issuance of subordinated notes payable. These warrants allow the
holders to purchase 4,651 and 23,332 shares of the Company's common
stock at $29.99 and $15.00 per share through April 30, 1996 and March
13, 1997, respectively. No warrants have been exercised.
During fiscal years 1995 and 1994, the Company performed product
development and manufacturing activities for a stockholder of the
Company. Revenue for these sales and services amounted to $9,869 and
$194,748 in fiscal years 1995 and 1994, respectively.
(7) NOTES PAYABLE TO MTDC
Notes payable to MTDC totaling $166,660 and $373,605 at March 31, 1995 and
1994, respectively, consist of unsecured subordinated borrowings, with
interest payable monthly at rates ranging from 9% to 12%. The notes
consist of $250,000 in borrowings dated April 30, 1991, payable in 36
monthly installments of approximately $6,944, commencing May 1, 1993,
and $200,000 in borrowings dated March 13, 1992, due on March 13, 1997.
Interest on the $250,000 note accrues on the unpaid principal balance
at 11% and is payable monthly in arrears on the first day of each
month. Interest on the $200,000 note accrues on the unpaid principal
balance at 12% and shall be paid monthly in arrears on the first day of
each month starting November 1, 1993, with the first eighteen months'
interest having been deferred and paid in equal installments over the
eighteen-month period commencing November 1, 1993. Interest expense
for notes payable to MTDC for the years ended March 31, 1995 and 1994,
amounted to $40,055 and $48,629.
On February 17, 1995, the Company signed a Note Restructuring Agreement
whereby the Company paid $200,000 to MTDC in settlement of the March
13, 1992 borrowing and signed an Amended and Restated Subordinated
Secured Promissory Note (the "Amended and Restated Note") in the amount
of $166,660, with interest at 9% per year, to restructure the balance
remaining under the April 30, 1991 borrowing. Under the Amended and
Restated Note, principal is repayable in 36 monthly installments of
$4,629 beginning on April 1, 1995, with the final installment payable
on March 1, 1998. In connection with the Note Restructuring Agreement,
MTDC agreed to return to the Company 16,906 warrants to purchase the
Company's common stock (note 8).
(8) STOCKHOLDERS' EQUITY
In June 1984, the Company adopted an Incentive Stock Option Plan ("ISOP").
The ISOP provides that the board of directors may grant options to
purchase shares of the Company's common stock to employees of the
Company at not less than the fair market value of the common stock at
the time of grant. The Company reserved 26,800 shares for issuance
under the ISOP. At March 31, 1995, 18,300 options are available under
the ISOP.
(Continued)
<PAGE>
4
NORFOLK SCIENTIFIC, INC.
Notes to Financial Statements
The Stock Appreciation Rights Plan ("SARP") allowed holders of outstanding
options under the ISOP to participate by agreeing to cancel their ISOP
shares. Some participants received more shares than previously awarded
under the ISOP; others received fewer. The SARP provides that the
board of directors set the terms of each particular award at the time
of the granting of such award, including, without limitation, the
identity of the grantee(s), vesting schedules, exercise price,
expiration date, number of shares subject to the award, and whether and
to what extent the award shall terminate upon termination of employment
or competitive activities. The SARP allows participants to acquire
common stock of the Company only if the Company is sold. Due to the
uncertainty of a sale and the Company's inability to reasonably
estimate the amount of proceeds if a sale were to occur, the Company
has not provided for any compensation expense related to the SARP.
During 1995, the board of directors authorized issuances of up to
20,000 shares under the SARP. At March 31, 1995, a total of 15,900
stock appreciation rights remain outstanding at a price of $1.50 per
share with vesting dates extending through January 1, 1997. The stock
appreciation rights expire at various dates through January 29, 2005.
The Company has granted 4,183 stock options under its 1985 Nonqualified
Stock Option Plan at per share option prices ranging from $18.75 to
$35.00. At March 31, 1995, 1,250 options remain outstanding and are
exercisable at option prices ranging from $18.75 to $35.00.
At March 31, 1995, the Company has warrants outstanding which allow the
holders to purchase 29,145 shares of the Company's common stock at
prices ranging from $15.00 to $29.99 per share. These warrants include
those originally issued to related parties (note 6) and MTDC (note 7).
The warrants issued to MTDC were returned to the Company for
cancellation in accordance with the terms of the agreement
restructuring the Company's debt with MTDC. These warrants were
reissued to the remaining holders of the notes.
(9) COMMITMENTS AND CONTINGENCIES
(A) LEASES
The Company leases office space under an operating lease agreement,
expiring on March 31, 1995. The Company renewed this lease for five
additional years beginning on April 1, 1995. In addition to base rent
due under the terms of the lease, beginning April 1, 1998, the lease
provides for additional rent calculated as the base rent adjusted for
the increase in the Consumer Price Index for All Urban Consumers.
Total rent expense was $95,703 and $93,939 for the years ended March
31, 1995 and 1994, respectively.
Future minimum lease payments are as follows:
<TABLE>
<CAPTION>
YEAR ENDED:
----------
<S> <C>
March 31, 1996 $ 91,432
March 31, 1997 88,383
March 31, 1998 85,932
March 31, 1999 85,932
March 31, 2000 85,932
---------
$ 437,611
---------
---------
</TABLE>
(Continued)
<PAGE>
5
NORFOLK SCIENTIFIC, INC.
Notes to Financial Statements
(B) ROYALTY AGREEMENTS
In 1989, the Company obtained exclusive worldwide rights to manufacture
and distribute a unit-dose product for clearing lipemic serum. In
consideration of this right, the Company agreed to pay royalties of
7-1/2% of net sales of the product, with a minimum royalty of $12,000
per year. This agreement expires on June 30, 1997. The Company
incurred $12,000 of royalty expense for the years ended March 31, 1995
and 1994, related to this agreement.
In 1993, the Company obtained the right from a related party to manufacture
and distribute a slide spinner centrifuge which creates a monolayer of
whole blood cells. In consideration of this right, the Company agreed
to pay royalties of 3-1/2% of net sales of the product and 1-1/2% of
net sales of related disposable products. If net sales of such
disposables reach $500,000 during the royalty period, the disposable
royalty will increase to 3% of net sales of related disposables. The
royalty period is for the five-year period beginning January 30, 1991.
The Company incurred $1,000 and $6,245 of royalty expense for the years
ended March 31, 1995 and 1994, respectively, related to this agreement.
(C) CONTINGENCIES
On April 22, 1994, the U.S. Food & Drug Administration (FDA) notified the
Company that the Company was not in compliance with the requirement of
Good Manufacturing Practice (GMP). The Company responded on May 10,
1994 and has taken steps to bring itself into compliance with GMP. The
FDA revisited the Company on March 9, 1995 and verbally informed
management that there were no material deficiencies that would warrant
a written notice. No provision has been made in the accompanying
financial statements for adjustments, if any, should the Company be
unsuccessful in satisfying the FDA's cirterion for GMP compliance.
(10) INCOME TAXES
For the years ended March 31, income tax expense consisted of:
<TABLE>
<CAPTION>
1995 1994
---- ----
<S> <C> <C>
State income taxes $ 456 906
Federal income taxes - effect of net operating loss
carryforward - -
----- ----
$ 456 906
----- ----
----- ----
</TABLE>
Actual tax expense for fiscal year 1995 differs from expected tax
computed applying the U.S. federal corporate income tax rate of
34% to income before taxes mainly due to the utilization of net operating
loss carryforwards and research and experimentation credits
carryforwards.
(Continued)
<PAGE>
6
NORFOLK SCIENTIFIC, INC.
Notes to Financial Statements
The tax effects of temporary differences that give rise to significant
portions of deferred tax assets and liabilities at March 31, 1995
and 1994, are as follows:
<TABLE>
<CAPTION>
1995 1994
---- ----
<S> <C> <C>
Deferred tax assets:
Tax loss carryforward $ 54,618 102,839
Inventory uniform capitalization 45,656 34,171
Accounts receivable allowance 18,442 19,974
Amortization of patents 1,951 674
Research and experimentation credits
carryforward 50,674 50,674
--------- --------
Gross deferred tax assets 171,341 208,332
Less: Valuation allowance (171,341) (197,776)
--------- --------
- 10,556
--------- --------
Deferred tax liabilities:
Research and development costs - (10,556)
--------- --------
Net deferred tax asset $ - -
--------- --------
--------- --------
</TABLE>
The valuation allowance for deferred tax assets as of April 1, 1994,
was $197,776. The net change in the total valuation allowance for the
year ended March 31, 1995, was a decrease of $26,435.
At March 31, 1995, the Company had net operating loss carryforwards of
approximately $161,000 to offset future federal income taxes. In
addition, at March 31, 1995, the Company had net operating loss
carryforwards of approximately $122,000 to offset future state income
taxes. The Company's net operating loss carryforwards may be subject
to limitation in the event that the Company experiences more than a 50%
change of stock ownership during a three-year period. At March 31,
1995, the Company also had research and experimentation credit
carryforwards of approximately $51,000. The net operating loss and
research and experimentation credit carryforwards expire at various
dates through the year 2007.
(11) 401(K) PLAN
In October 1993, the Company adopted a deferred compensation plan (the
"Plan"). Employees with one or more years of service are eligible to
participate in the Plan. The Plan requires the Company to match
employee contributions up to $500 annually. The Company incurred
$4,298 and $9,625 for fiscal years 1995 and 1994, respectively, related
to the employer match under the Plan.
(12) SIGNIFICANT CUSTOMERS
The Company sells primarily to laboratories, hospitals and doctors'
offices. Included in accounts receivable at March 31, 1995 are amounts
from two customers representing approximately 49% of net accounts
receivable. Additionally, 43% and 45% of net sales were to the same
two customers during the years ended March 31, 1995 and 1994,
respectively.
<PAGE>
NORFOLK SCIENTIFIC, INC.
D/B/A STATSPIN TECHNOLOGIES
Financial Statements
March 31, 1994 and 1993
(With Independent Auditors' Report Thereon)
<PAGE>
[KPMG Peat Marwick LLP Letterhead]
INDEPENDENT AUDITORS' REPORT
The Board of Directors
Norfolk Scientific, Inc.:
We have audited the accompanying balance sheets of Norfolk Scientific, Inc. as
of March 31, 1994 and 1993, and the related statements of operations and
accumulated deficit, and cash flows for the years then ended. These financial
statements are the responsibility of the Company's management. Our
responsibility is to express an opinion on these financial statements based on
our audits.
We conducted our audits in accordance with generally accepted auditing
standards. Those standards require that we plan and perform the audit to obtain
reasonable assurance about whether the financial statements are free of material
misstatement. An audit includes examining, on a test basis, evidence supporting
the amounts and disclosures in the financial statements. An audit also includes
assessing the accounting principles used and significant estimates made by
management, as well as evaluating the overall financial statement presentation.
We believe that our audits provide a reasonable basis for our opinion.
In our opinion, the financial statements referred to above present fairly, in
all material respects, the financial position of Norfolk Scientific, Inc. at
March 31, 1994 and 1993, and the results of its operations and its cash flows
for the years then ended, in conformity with generally accepted accounting
principles.
KPMG Peat Marwick LLP
May 27, 1994, except as to note 7 which
is as of February 17, 1995 and note 5
which is as of March 16, 1995
<PAGE>
NORFOLK SCIENTIFIC, INC.
Balance Sheets
March 31, 1994 and 1993
<TABLE>
<CAPTION>
ASSETS (note 5) 1994 1993
---- ----
<S> <C> <C>
Current assets:
Cash (note 3) $ 283,202 303,206
Accounts receivable, trade, less allowance for doubtful accounts
of $58,748 in 1994 and $20,476 in 1993 (note 12) 456,344 417,720
Inventories, net (note 4) 680,915 510,759
Prepaid expenses 13,677 13,791
----------- ----------
Total current assets 1,434,138 1,245,476
----------- ----------
Property and equipment:
Manufacturing equipment 409,104 322,265
Furniture and fixtures 76,613 70,179
----------- ----------
485,717 392,444
Less accumulated depreciation 327,681 247,810
----------- ----------
Net property and equipment 158,036 144,634
----------- ----------
Other assets, net 43,912 38,374
----------- ----------
$ 1,636,086 1,428,484
----------- ----------
----------- ----------
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Note payable to bank (note 5) $ 250,116 94,954
Current portion of subordinated notes payable to stockholders
(note 6) 25,164 23,067
Current portion of subordinated notes payable to MTDC (note 7) 200,000 76,384
Accounts payable, trade 288,998 130,205
Accrued expenses 200,295 178,431
Deferred revenue 6,650 40,000
Customer deposits - 34,625
State income taxes payable 1,768 4,612
----------- ----------
Total current liabilities 972,991 582,278
----------- ----------
Subordinated notes payable to stockholders, less current maturities
(note 6) 177,258 202,433
Subordinated notes payable to MTDC, less current maturities (note 7) 173,605 373,616
----------- ----------
Total liabilities 350,863 1,158,327
----------- ----------
Commitments and contingencies (notes 9 and 11)
Stockholders' equity (notes 6, 7 and 8):
Common stock, $1 par value. Authorized 300,000 shares;
issued and outstanding 69,771 shares 69,771 69,771
Additional paid-in capital 732,211 732,211
Accumulated deficit (489,750) (531,825)
----------- ----------
Total stockholders' equity 312,232 270,157
----------- ----------
$ 1,636,086 1,428,484
----------- ----------
----------- ----------
</TABLE>
See accompanying notes to financial statements.
<PAGE>
NORFOLK SCIENTIFIC, INC.
Statements of Operations and Accumulated Deficit
Years ended March 31, 1994 and 1993
<TABLE>
<CAPTION>
1994 1993
---- ----
<S> <C> <C>
Net sales (note 12) $ 3,450,251 3,123,229
Cost of sales 2,038,342 1,831,759
----------- ----------
Gross profit 1,411,909 1,291,470
----------- ----------
Operating expenses:
Research and development 413,016 334,029
Selling, general, and administrative 879,237 723,373
----------- ----------
Total operating expenses 1,292,253 1,057,402
----------- ----------
Income from operations 119,656 234,068
----------- ----------
Interest income (expense):
Interest income 5,224 10,540
Interest expense (81,899) (82,916)
----------- ----------
Interest expense, net (76,675) (72,376)
----------- ----------
Income before income taxes and extraordinary item 42,981 161,692
Provision for income taxes (note 10) 906 56,718
----------- ----------
Income before extraordinary item 42,075 104,974
Extraordinary item - income tax benefit of loss
carryforwards (note 10) - 52,106
----------- ----------
Net income 42,075 157,080
Accumulated deficit, beginning of year (531,825) (688,905)
----------- ----------
Accumulated deficit, end of year $ (489,750) (531,825)
----------- ----------
----------- ----------
</TABLE>
See accompanying notes to financial statements.
<PAGE>
NORFOLK SCIENTIFIC, INC.
Statements of Cash Flows
Years ended March 31, 1994 and 1993
<TABLE>
<CAPTION>
1994 1993
---- ----
<S> <C> <C>
Cash flows from operating activities:
Net income $ 42,075 157,080
Adjustments to reconcile net income to net cash provided
(used) by operating activities:
Depreciation and amortization 89,559 73,761
Changes in assets and liabilities:
Accounts receivable, net (38,624) (195,245)
Inventories, net (170,156) (223,336)
Prepaid expenses 114 5,151
Accounts payable, trade 158,793 10,423
Accrued expenses 21,864 27,245
Deferred revenue (33,350) 40,000
Customer deposits (34,625) 34,625
State income taxes payable (2,844) 4,612
--------- ---------
Net cash provided (used) by operating activities 32,806 (65,684)
--------- ---------
Cash flows from investing activities:
Additions to property and equipment (93,273) (96,355)
Increase in other assets, net (15,226) (3,329)
--------- ---------
Net cash used by investing activities (108,499) (99,684)
--------- ---------
Cash flows from financing activities:
Net increase in line of credit borrowings 155,162 94,954
Repayments on notes payable to stockholders (23,078) -
Repayments on notes payable to MTDC (76,395) -
--------- ---------
Net cash provided by financing activities 55,689 94,954
--------- ---------
Net decrease in cash (20,004) (70,414)
Cash, beginning of year 303,206 373,620
--------- ---------
Cash, end of year $ 283,202 303,206
--------- ---------
--------- ---------
Supplemental disclosures of cash flow information:
Cash paid during the year for interest $ 76,384 53,076
--------- ---------
--------- ---------
Cash paid during the year for taxes $ 3,750 -
--------- ---------
--------- ---------
</TABLE>
See accompanying notes to financial statements.
<PAGE>
NORFOLK SCIENTIFIC, INC.
Notes to Financial Statements
March 31, 1994 and 1993
(1) NATURE OF BUSINESS
Norfolk Scientific, Inc. (d/b/a StatSpin Technologies) was incorporated on
June 11, 1984, as a successor to Kelley, Newhouse & Company, a
partnership. The Company purchased assets and rights from its predecessor
to engage in the development, manufacture, and sale of medical and
laboratory equipment and supplies.
(2) SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
(A) INVENTORIES
Inventories are stated at the lower of cost or market, cost being determined
using the first-in, first-out (FIFO) method.
(B) PROPERTY AND EQUIPMENT
Property and equipment is stated at cost. Depreciation is provided using an
accelerated method over the estimated useful lives of the respective
assets.
(C) OTHER ASSETS, NET
Other assets consist principally of patents, stated at cost, net of
accumulated amortization. The cost of patents is amortized using the
straight-line method over the estimated useful lives of the respective
patents.
(D) INCOME TAXES
The Financial Accounting Standards Board has issued Statement 109,
"Accounting for Income Taxes." Statement 109 requires a change from the
deferred method required under APB Opinion 11 to the asset and liability
method. Under the deferred method, annual income tax expense is matched
with pretax accounting income by providing deferred taxes at current tax
rates for timing differences between the determination of net income for
financial reporting and tax purposes. The objective of the asset and
liability method is to establish deferred tax assets and liabilities for
the temporary differences between the financial reporting basis and the
tax basis of the Company's assets and liabilities at enacted tax rates
expected to be in effect when such amounts are to be realized or settled.
Under Statement 109, the effect on deferred tax assets and liabilities
of change in tax rates is recognized in income in the period that
includes the enactment date.
Effective April 1, 1993, the Company adopted Statement 109. The cumulative
effect of the change in the method of accounting for income taxes is not
material and therefore is not presented separately in the accompanying
statements of operations and accumulated deficit for the year ended
March 31, 1994. Prior years' financial statements have not been restated
to apply the provisions of Statement 109.
(E) RECLASSIFICATIONS
Certain reclassifications have been made to the fiscal 1993 financial
statements to conform to the fiscal 1994 presentation.
(Continued)
<PAGE>
2
NORFOLK SCIENTIFIC, INC.
Notes to Financial Statements
(3) RESTRICTED CASH
The entire cash balance as of March 31, 1994 and 1993 is restricted. This
cash is available for operating uses with the approval of Company's board
of directors and the Massachusetts Technology Development Corporation
("MTDC") (see note 7).
(4) INVENTORIES
Inventories consist of the following at March 31:
<TABLE>
<CAPTION>
1994 1993
---- ----
<S> <C> <C>
Raw materials $ 584,454 421,733
Work in process 98,496 102,223
Finished goods 78,754 45,925
---------- ---------
761,704 569,881
Less: Reserve for obsolescence (80,789) (59,122)
---------- ---------
$ 680,915 510,759
---------- ---------
---------- ---------
</TABLE>
(5) NOTE PAYABLE TO BANK
Note payable to bank consists of borrowings under a $300,000 line of credit
($100,000 in 1993), expiring on July 31, 1994, that is secured by all of
the assets of the Company. Under the line of credit the Company can
borrow up to 75% (70% in 1993) of any of its accounts receivable
balances, excluding those that have invoices outstanding for over
90 days. Interest is payable monthly at the bank's base rate
plus 2% (8.25% and 8.5% at March 31, 1994 and 1993, respectively).
The Company had $250,116 and $94,954 of outstanding borrowings at
March 31, 1994 and 1993, respectively.
The line of credit agreement has been renewed and extended through
September 30, 1995.
(6) RELATED PARTY TRANSACTIONS
Notes payable to stockholders totaling $202,422 and $225,500 at March 31,
1994 and 1993, respectively, consist of unsecured subordinated borrowings
with interest payable monthly. The notes consist of $75,500 in borrowings
dated April 30, 1991, payable in 36 monthly installments of approximately
$2,097, commencing May 1, 1993, and $150,000 in borrowings dated March 13,
1992, due on March 13, 1997. Interest on the $75,500 note accrues on the
unpaid principal balance at 11% and is payable monthly in arrears on the
first day of each month starting November 1, 1991, with the first six
months' interest having been deferred and paid in equal installments over
the eighteen-month period commencing November 1, 1991. Interest on the
$150,000 note accrues on the unpaid principal balance at 12% and is
payable monthly in arrears on the first day of each month starting
November 1, 1993, with the first eighteen months' interest having been
deferred and paid in equal installments over the eighteen-month period
commencing November 1, 1993. Interest expense for notes payable to
stockholders for the years ended March 31, 1994 and 1993, amounted to
$25,899 and $26,305, respectively.
(Continued)
<PAGE>
3
NORFOLK SCIENTIFIC, INC.
Notes to Financial Statements
Under the notes payable agreements, the Company is required to comply with
various restrictive covenants. As of March 31, 1994, the Company was not
in compliance with certain covenants. The Company has received a waiver
of such defaults from a majority of the noteholders as of March 31, 1994.
In addition, 1,079 and 9,999 warrants, respectively, were issued to related
parties in connection with the April 30, 1991 and March 13, 1992 issuance
of subordinated notes payable. These warrants allow the holders to
purchase 1,079 and 9,999 shares of the Company's common stock at $29.99
and $15.00 per share through April 30, 1996 and March 13, 1997,
respectively. Upon the issuance of the March 13, 1992 warrants, the
April 30, 1991 warrant price (originally $35.00) was adjusted downward
to $29.99 pursuant to Section 4(a) of the warrant agreement. No
warrants have been exercised.
During fiscal years 1994 and 1993, the Company performed product development
and manufacturing activities for a stockholder of the Company. Revenue
for these sales and services amounted to $194,748 and $27,320 in fiscal
years 1994 and 1993, respectively.
(7) NOTES PAYABLE TO MTDC
Notes payable to MTDC totaling $373,605 and $450,000 at March 31, 1994 and
1993, respectively, consist of unsecured subordinated borrowings, with
interest payable monthly at rates ranging from 11% to 12%. The notes
consist of $250,000 in borrowings dated April 30, 1991, payable in 36
monthly installments of approximately $6,944, commencing May 1, 1993, and
$200,000 in borrowings dated March 13, 1992, due on March 13, 1997.
Interest on the $250,000 note accrues on the unpaid principal balance at
11% and is payable monthly in arrears on the first day of each month
starting November 1, 1991, with the first six months' interest having been
deferred and paid in equal installments over the eighteen-month period
commencing November 1, 1991. Interest on the $200,000 note accrues on the
unpaid principal balance at 12% and shall be paid monthly in arrears on
the first day of each month starting November 1, 1993, with the first
eighteen months' interest having been deferred and paid in equal
installments over the eighteen-month period commencing November 1, 1993.
Interest expense for notes payable to MTDC for the years ended March 31,
1994 and 1993, amounted to $48,629 and $51,500.
On February 17, 1995, the Company signed a Note Restructuring Agreement
whereby the Company paid $200,000 to MTDC in settlement of the March 13,
1992 borrowing and signed an Amended and Restated Subordinated Secured
Promissory Note (the "Amended and Restated Note") in the amount of
$166,660, with interest at 9% per year, to restructure the balance
remaining under the April 30, 1991 borrowing. Under the Amended and
Restated Note, principal is repayable in 36 monthly installments of $4,629
beginning on April 1, 1995, with the final installment payable on February
1, 1998. In connection with the Note Restructuring Agreement, MTDC agreed
to return to the Company 16,906 warrants to purchase the Company's common
stock (note 8).
The balance sheet at March 31, 1994 has been adjusted to reflect
indebtedness to MTDC under the terms of the Note Restructuring Agreement.
(Continued)
<PAGE>
4
NORFOLK SCIENTIFIC, INC.
Notes to Financial Statements
(8) STOCKHOLDERS' EQUITY
In June 1984, the Company adopted an Incentive Stock Option Plan ("ISOP").
The ISOP provides that the board of directors may grant options to
purchase shares of the Company's common stock to employees of the Company
at not less than the fair market value of the common stock at the time of
grant. The Company reserved 26,800 shares for issuance under the ISOP.
At March 31, 1994, 18,300 options are available under the ISOP.
The Stock Appreciation Rights Plan ("SARP") allowed holders of outstanding
options under the ISOP to participate by agreeing to cancel their ISOP
shares. Some participants received more shares than previously awarded
under the ISOP; others received fewer. The SARP provides that the board
of directors set the terms of each particular award at the time of the
granting of such award, including, without limitation, the identity of the
grantee(s), vesting schedules, exercise price, expiration date, number of
shares subject to the award, and whether and to what extent the award
shall terminate upon termination of employment or competitive activities.
The SARP allows participants to acquire common stock of the Company only
if the Company is sold. Due to the uncertainty of a sale and the
Company's inability to reasonably estimate the amount of proceeds if a
sale were to occur, the Company has not provided for any compensation
expense related to the SARP. During 1994, the board of directors
authorized issuances of up to 20,000 shares under the SARP. At March 31,
1994, a total of 17,900 stock appreciation rights remain outstanding
at a price of $1.50 per share with vesting dates extending through
January 1, 1997. The stock appreciation rights expire at various
dates through January 29, 2005.
The Company has granted 4,183 stock options under its 1985 Nonqualified
Stock Option Plan at per share option prices ranging from $18.75 to
$35.00. At March 31, 1994, 1,250 options remain outstanding and
are exercisable at option prices ranging from $18.75 to $35.00.
At March 31, 1994, the Company has warrants outstanding which allow the
holders to purchase 29,145 shares of the Company's common stock at prices
ranging from $15.00 to $29.99 per share. These warrants include those
issued to related parties (note 6) and MTDC (note 7) during 1992, as well
as 1,000 warrants previously issued and subsequently increased to 1,161
warrants pursuant to Section 6.4 of the warrant agreement dated January
23, 1989.
(9) COMMITMENTS AND CONTINGENCIES
(A) LEASES
The Company leases office space under an operating lease agreement,
expiring on March 31, 1995. The Company, at its option, may extend the
term of the lease for an additional five-year period. In addition to
base rent due under the terms of the lease, beginning April 1, 1993, the
lease provides for additional rent calculated as the base rent adjusted
for the increase in the Consumer Price Index for All Urban Consumers.
Such additional rent is adjusted biannually. Total rent expense was
$93,939 and $87,662 for the years ended March 31, 1994 and 1993,
respectively.
Future minimum lease payments are as follows:
<TABLE>
<CAPTION>
YEAR ENDED:
----------
<S> <C>
March 31, 1995 $ 92,639
--------
--------
</TABLE>
(Continued)
<PAGE>
5
NORFOLK SCIENTIFIC, INC.
Notes to Financial Statements
(B) ROYALTY AGREEMENTS
In 1989, the Company obtained exclusive worldwide rights to manufacture and
distribute a unit-dose product for clearing lipemic serum. In
consideration of this right, the Company agreed to pay royalties of 7-
1/2% of net sales of the product, with a minimum royalty of $12,000 per
year. This agreement expires on June 30, 1994. The Company incurred
$12,000 of royalty expense for the years ended March 31, 1994 and 1993,
related to this agreement.
During the year ended March 31, 1993, the Company obtained the right from a
related party to manufacture and distribute a slide spinner centrifuge
which creates a monolayer of whole blood cells. In consideration of this
right, the Company agreed to pay royalties of 3-1/2% of net sales of the
product and 1-1/2% of net sales of related disposable products. If net
sales of such disposables reach $500,000 during the royalty period, the
disposable royalty will increase to 3% of net sales of related
disposables. The royalty period is for the five-year period beginning
January 30, 1991. The Company incurred $6,245 and $12,317 of royalty
expense for the years ended March 31, 1994 and 1993, respectively,
related to this agreement.
(C) CONTINGENCIES
On April 22, 1994, the U.S. Food & Drug Administration (FDA) notified the
Company that the Company was not in compliance with the requirement of
Good Manufacturing Practice (GMP). The Company responded on May 10, 1994
and has taken steps to bring itself into compliance with GMP. The FDA
has agreed to put the Company on the list for re-inspection. Management
believes that the Company will be found in GMP compliance in the
forthcoming re-inspection. No provision has been made in the
accompanying financial statements for adjustments, if any, should the
Company be unsuccessful in satisfying the FDA s criterion for GMP
compliance.
(10) INCOME TAXES
For the years ended March 31, income tax expense consisted of:
<TABLE>
<CAPTION>
1994 1993
---- ----
<S> <C> <C>
State income taxes $ 906 4,612
Federal income taxes - effect of net operating loss
carryforward - 52,106
----- ------
$ 906 56,718
----- ------
----- ------
</TABLE>
Actual tax expense for fiscal year 1994 differs from expected tax computed
applying the U.S. federal corporate income tax rate of 34% to income
before taxes mainly due to the utilization of net operating loss
carryforwards and research and experimentation credits carryforwards.
(Continued)
<PAGE>
6
NORFOLK SCIENTIFIC, INC.
Notes to Financial Statements
The tax effects of temporary differences that give rise to significant
portions of deferred tax assets and liabilities at March 31, 1994, are as
follows:
<TABLE>
<S> <C>
Deferred tax assets:
Tax loss carryforward $ 102,839
Inventory uniform capitalization 34,171
Accounts receivable allowance 19,974
Amortization of patents 674
Research and experimentation credits carryforward 50,674
----------
Gross deferred tax assets 208,332
Less: Valuation allowance (197,776)
----------
10,556
----------
Deferred tax liabilities:
Research and development costs (10,556)
----------
Net deferred tax asset $ -
----------
----------
</TABLE>
The valuation allowance for deferred tax assets as of April 1, 1993, was
$215,210. The net change in the total valuation allowance for the year
ended March 31, 1994, was a decrease of $17,434.
At March 31, 1994, the Company had net operating loss carryforwards of
approximately $302,000 to offset future federal income taxes. In
addition, at March 31, 1994, the Company had net operating loss
carryforwards of approximately $168,000 to offset future state income
taxes. The Company's net operating loss carryforwards may be subject to
limitation in the event that the Company experiences more than a 50%
change of stock ownership during a three-year period. At March 31, 1994,
the Company also had research and experimentation credit carryforwards of
approximately $51,000. The net operating loss and research and
experimentation credit carryforwards expire at various dates through the
year 2007.
(11) 401(K) PLAN
In October 1993, the Company adopted a deferred compensation plan (the
"Plan"). Employees with one or more years of service are eligible to
participate in the Plan. The Plan requires the Company to match employee
contributions up to $500 annually. During fiscal year 1994, the Company
incurred $9,625 related to the employer match under the Plan.
(12) SIGNIFICANT CUSTOMERS
The Company sells primarily to laboratories, hospitals and doctors'
offices. Included in accounts receivable at March 31, 1994 are amounts
from two customers representing approximately 39% of net accounts
receivable. Additionally, 45% and 38% of net sales were to the same
customer during the years ended March 31, 1994 and 1993, respectively.
<PAGE>
UNAUDITED PRO FORMA CONDENSED COMBINED
FINANCIAL STATEMENTS
The combination of International Remote Imaging Systems ("IRIS") and Norfolk
Scientific, Inc., doing business as StatSpin Technologies ("StatSpin") is
expected to be accounted for using the pooling-of-interests method of accounting
which accounts for a business combination as the uniting of the ownership
interests by exchange of equity securities. Under this method of accounting,
ownership interests continue and the former bases of accounting are retained;
the recorded assets and liabilities of IRIS and StatSpin are carried forward to
the combined corporation at their recorded amounts; income of the combined
corporation includes income of IRIS and StatSpin for the entire fiscal period in
which the combination occurs; and the reported income of the separate
corporations for prior periods is combined and restated as income of the
combined corporation.
The accompanying Unaudited Pro Forma Condensed Combined Balance Sheet combines
the balance sheets of IRIS and StatSpin as of September 30, 1995. The annual
Unaudited Pro Forma Condensed Combined Statements of Income combine the
statements of income of IRIS for the fiscal years ended December 31, 1992, 1993
and 1994 with those of StatSpin for the fiscal years ended March 31, 1993, 1994
and 1995. The statements of income for StatSpin included in the Unaudited Pro
Forma Condensed Combined Statements of Income for the nine months ended
September 30, 1995 and 1994 have been recast to conform with IRIS's fiscal year
end.
The Unaudited Pro Forma Condensed Combined Financial Statements are based upon
the respective historical financial statements of IRIS and StatSpin and should
be read in conjunction with those historical financial statements and the
related notes thereto, and with the Notes to Unaudited Pro Forma Condensed
Combined Financial Statements. The Pro Forma Condensed Combined Financial
Statements do not purport to be indicative of the results which would actually
have been obtained if the merger had been effected on the date or dates
indicated or which may be obtained in the future.
<PAGE>
UNAUDITED PRO FORMA CONDENSED COMBINED
BALANCE SHEET
SEPTEMBER 30, 1995
<TABLE>
<CAPTION>
Historical Historical Pro Forma Pro Forma
IRIS StatSpin Adjustments Combined
---- -------- ----------- ---------
ASSETS
<S> <C> <C> <C> <C>
Cash and cash equivalents $1,666,297 $219,426 $1,885,723
Short-term investments 4,697,770 4,697,770
Accounts receivable - trade 2,108,558 419,621 2,528,179
Accounts receivable - other 723,299 723,299
Inventories 2,645,867 411,739 3,057,606
Prepaid expenses and other 160,703 8,109 168,812
----------- ---------- -----------
Total current assets 12,002,494 1,058,895 13,061,389
Property and equipment, net 677,026 75,576 752,602
Software development costs, net 185,803 185,803
Long term investments 100,000 100,000
Deferred tax asset 594,000 594,000
Other assets 2,644,415 42,000 2,686,415
----------- ---------- -----------
Total assets $16,203,738 $1,176,471 $17,380,209
----------- ---------- -----------
----------- ---------- -----------
LIABILITIES AND SHAREHOLDERS' EQUITY
Notes payable $180,815 $180,815
Accounts payable $757,563 140,556 898,119
Accrued expenses 821,835 100,289 922,124
Service contracts - deferred income 771,115 25,000 796,115
----------- ---------- -----------
Total current liabilities 2,350,513 446,660 2,797,173
Notes payable 150,000 150,000
Service contracts - deferred income 278,918 278,918
----------- ---------- -----------
Total liabilities 2,629,431 596,660 3,226,091
Common stock 60,089 69,771 (66,370) 63,490
Additional paid in capital 32,609,313 732,211 66,370 33,407,894
Treasury stock (453,386) (453,386)
Unearned compensation (74,657) (74,657)
Accumulated deficit (18,567,052) (222,171) (18,789,223)
----------- ---------- -----------
Total shareholders' equity 13,574,307 579,811 14,154,118
----------- ---------- -----------
Total liabilities and
shareholders' equity $16,203,738 $1,176,471 $17,380,209
----------- ---------- -----------
----------- ---------- -----------
</TABLE>
See accompanying notes
<PAGE>
UNAUDITED PRO FORMA CONDENSED COMBINED
STATEMENTS OF INCOME
<TABLE>
<CAPTION>
HISTORICAL HISTORICAL
-------------------------------------- ------------------------------------------
IRIS StatSpin IRIS StatSpin
Nine Months Nine Months Nine Months Nine Months
Ended Ended Ended Ended
September September Pro Forma September September Pro Forma
30, 1994 30, 1994 Combined 30, 1995 30, 1995 Combined
-------- -------- -------- -------- -------- --------
<S> <C> <C> <C> <C> <C> <C>
Sales of medical equipment and supplies $5,232,321 $2,351,952 $7,584,273 $6,655,826 $2,155,578 $8,811,404
Service contracts and repairs 1,551,037 69,784 1,620,821 1,744,103 71,292 1,815,395
Research and development contracts 551,266 551,266 794,719 794,719
---------- ---------- ---------- ----------- ----------- -----------
Net revenues 7,334,624 2,421,736 9,756,360 9,194,648 2,226,870 11,421,518
Cost of goods from equipment and supplies 2,178,769 1,500,967 3,679,736 2,746,118 1,335,137 4,081,255
Cost of goods from service contracts 1,310,155 1,310,155 1,169,314 1,169,314
Cost of research and development contracts 686,266 686,266 883,710 883,710
---------- ---------- ---------- ----------- ----------- -----------
Cost of goods sold 4,175,190 1,500,967 5,676,157 4,799,142 1,335,137 6,134,279
---------- ---------- ---------- ----------- ----------- -----------
Gross margin 3,159,434 920,769 4,080,203 4,395,506 891,733 5,287,239
Marketing and selling expenses 1,312,358 364,742 1,677,100 1,756,865 327,854 2,084,719
General and administrative expenses 925,644 247,481 1,173,125 1,188,055 222,840 1,410,895
Research and development expenses 222,255 195,015 417,270 373,600 114,147 487,747
Acquisition of in-process technology 3,480,987 3,480,987
---------- ---------- ---------- ----------- ----------- -----------
Total 2,460,257 807,238 3,267,495 6,799,507 664,841 7,464,348
Operating income (loss) 699,177 113,531 812,708 (2,404,001) 226,892 (2,177,109)
Interest income (expense), net 113,647 (60,259) 53,388 207,150 (31,425) 175,725
Other income 100,655 463 101,118 83,848 9,853 93,701
---------- ---------- ---------- ----------- ----------- -----------
Income (loss) before taxes 913,479 53,735 967,214 (2,113,003) 205,320 (1,907,683)
Income taxes 21,000 1 21,001 30,000 (1,100) 28,900
---------- ---------- ---------- ----------- ----------- -----------
Net income (loss) $892,479 $53,734 $946,213 ($2,143,003) $206,420 ($1,936,583)
---------- ---------- ---------- ----------- ----------- -----------
---------- ---------- ---------- ----------- ----------- -----------
Net income (loss) per share $0.17 $0.17 ($0.40) ($0.34)
---------- ---------- ----------- -----------
---------- ---------- ----------- -----------
Weighted average shares and common
equivalent shares outstanding 5,314,773 5,687,008 5,405,526 5,777,761
---------- ---------- ----------- -----------
---------- ---------- ----------- -----------
</TABLE>
See accompanying notes
<PAGE>
UNAUDITED PRO FORMA CONDENSED COMBINED
STATEMENTS OF INCOME
<TABLE>
<CAPTION>
HISTORICAL HISTORICAL
--------------------------------------- ----------------------------------------
IRIS StatSpin IRIS StatSpin
Year Year Year Year
Ended Ended Ended Ended
December March 31, Pro Forma December March 31, Pro Forma
31, 1992 1993 Combined 31, 1993 1994 Combined
---------- ---------- ---------- ---------- ---------- ----------
<S> <C> <C> <C> <C> <C> <C>
Sales of medical equipment and supplies $6,371,499 $3,123,229 $9,494,728 $7,499,703 $3,450,251 $10,949,954
Service contracts and repairs 1,328,498 1,328,498 1,524,591 1,524,591
Research and development contracts 106,821 106,821 457,160 457,160
---------- ---------- ---------- ---------- ---------- -----------
Net revenues 7,806,818 3,123,229 10,930,047 9,481,454 3,450,251 12,931,705
Cost of goods from equipment and supplies 2,505,325 1,831,759 4,337,084 2,976,078 2,038,342 5,014,420
Cost of goods from service contracts 1,225,554 1,225,554 1,327,318 1,327,318
Cost of research and development contracts 326,204 326,204 637,552 637,552
---------- ---------- ---------- ---------- ---------- -----------
Cost of goods sold 4,057,083 1,831,759 5,888,842 4,940,948 2,038,342 6,979,290
---------- ---------- ---------- ---------- ---------- -----------
Gross margin 3,749,735 1,291,470 5,041,205 4,540,506 1,411,909 5,952,415
Selling, general and administrative expenses 2,716,993 723,373 3,440,366 2,979,011 879,237 3,858,248
Research and development expense 397,307 334,029 731,336 367,723 413,016 780,739
---------- ---------- ---------- ---------- ---------- -----------
Total 3,114,300 1,057,402 4,171,702 3,346,734 1,292,253 4,638,987
Operating income (loss) 635,435 234,068 869,503 1,193,772 119,656 1,313,428
Interest income (expense), net 88,510 (72,376) 16,134 105,232 (76,675) 28,557
Other income 112,500 112,500 38,558 38,558
---------- ---------- ---------- ---------- ---------- -----------
Income before taxes 836,445 161,692 998,137 1,337,562 42,981 1,380,543
Income taxes 64,068 4,612 68,680 57,000 906 57,906
---------- ---------- ---------- ---------- ---------- -----------
Net income $772,377 $157,080 $929,457 $1,280,562 $42,075 $1,322,637
---------- ---------- ---------- ---------- ---------- -----------
---------- ---------- ---------- ---------- ---------- -----------
Net income per share $0.16 $0.18 $0.26 $0.25
---------- ---------- ---------- -----------
---------- ---------- ---------- -----------
Weighted average shares and common
equivalent shares outstanding 4,928,223 5,300,458 4,979,785 5,352,020
---------- ---------- ---------- -----------
---------- ---------- ---------- -----------
<CAPTION>
HISTORICAL
-------------------------------------------
IRIS StatSpin
Year Year
Ended Ended
December March 31, Pro Forma
31, 1994 1995 Combined
----------- ---------- ------------
<S> <C> <C> <C>
Sales of medical equipment and supplies $7,430,489 $2,918,212 $10,348,701
Service contracts and repairs 2,153,076 2,153,076
Research and development contracts 1,078,378 1,078,378
----------- ---------- -----------
Net revenues 10,661,943 2,918,212 13,580,155
Cost of goods from equipment and supplies 2,922,084 1,824,913 4,746,997
Cost of goods from service contracts 1,752,031 1,752,031
Cost of research and development contracts 1,258,405 1,258,405
----------- ---------- -----------
Cost of goods sold 5,932,520 1,824,913 7,757,433
----------- ---------- -----------
Gross margin 4,729,423 1,093,299 5,822,722
Selling, general and administrative expenses 3,129,498 682,426 3,811,924
Research and development expense 321,391 194,313 515,704
----------- ---------- -----------
Total 3,450,889 876,739 4,327,628
Operating income (loss) 1,278,534 216,560 1,495,094
Interest income (expense), net 162,112 (67,426) 94,686
Other income 111,240 111,240
----------- ---------- -----------
Income before taxes 1,551,886 149,134 1,701,020
Income taxes 79,000 456 79,456
----------- ---------- -----------
Net income $1,472,886 $148,678 $1,621,564
----------- ---------- -----------
----------- ---------- -----------
Net income per share $0.28 $0.28
----------- -----------
----------- -----------
Weighted average shares and common
equivalent shares outstanding 5,323,108 5,695,343
----------- -----------
</TABLE>
See accompanying notes
<PAGE>
NOTES TO UNAUDITED PRO FORMA CONDENSED COMBINED
FINANCIAL STATEMENTS
1. Periods Presented
The annual Unaudited Pro Forma Condensed Combined Financial Statements have been
prepared by combining the separate historical financial statements of IRIS and
StatSpin for their historical fiscal periods. The historical financial
information of StatSpin included in the Unaudited Pro Forma Condensed Combined
Statements of Income for the nine months ended September 30, 1995 and 1994 have
been recast to conform with IRIS's fiscal year end.
The Unaudited Pro Forma Condensed Combined Balance Sheet as of September 30,
1995 reflects the issuance of approximately 340,179 shares of IRIS common stock
in exchange for all shares of StatSpin common stock (including common stock
attributable to stock appreciation rights) outstanding at September 30, 1995,
based upon an exchange ratio of 4.0950 shares of IRIS common stock (assuming an
IRIS stock price of $7.58 per share) for each share of StatSpin common stock.
2. Earnings Per Share
The unaudited pro forma net income (loss) per common and common equivalent share
outstanding was computed based on the combined weighted average number of shares
of common stock and common stock equivalents of IRIS and StatSpin outstanding
based upon an exchange ratio of 4.0950 shares of IRIS common stock for each
share of StatSpin common stock (including common stock attributable to stock
appreciation rights); a warrant to purchase 4.0950 shares of IRIS common stock
for each outstanding StatSpin warrant; and an option to purchase 4.0950 shares
of IRIS common stock for each outstanding StatSpin warrant.
3. Pro Forma Adjustments
The only pro forma adjustment is to restate common stock and paid in capital for
the difference in the par value of StatSpin common stock surrendered and the par
value of IRIS common stock issued.
The Unaudited Pro Forma Condensed Combined Financial Statements contain one
adjustment to conform the accounting policies of the two companies. IRIS
retroactively adopted the accounting standards required by Statement of
Financial Accounting Standards No. 109, "Accounting for Income Taxes" ("FAS
109") effective January 1, 1991. StatSpin adopted the standards required by FAS
109 effective April 1, 1993. The Unaudited Pro Forma Condensed Combined
Statement of Income for 1992 contains an adjustment to reflect both IRIS and
StatSpin adopting the standards required by FAS 109 effective January 1, 1991.
The effect of this adjustment on the combined historical financial data as
presented herein was a reclassification of the utilization of a net operating
loss carryforward from an extraordinary item
<PAGE>
to an offset against the income tax provision because utilization of net
operating loss carryforwards is not treated as an extraordinary item under
SFAS 109.
No provision has been reflected in the Unaudited Pro Forma Condensed Combined
Financial Statements for direct expenses related to the merger. IRIS and
StatSpin anticipate that the aggregate expenses and fees for the Merger will be
between $100,000 and $200,000.
4. Nonrecurring Item
The historical financial statements of IRIS for the nine months ended September
30, 1995 include a nonrecurring, noncash charge of $3,480,987 for the
acquisition of in-process research and development.
